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Diabetes Impairs Fracture Healing Through Foxo1-Mediated Downregulation of
IFT80 and Disruption of Ciliogenesis
Abstract
Objective: Impaired fracture healing in diabetic patients remains a clinical challenge. Diabetes adversely
affects chondrocytes, osteoblasts and their progenitors through various mechanisms such as increased
inflammatory cytokine expression, enhanced reactive oxygen species production and reduction in growth
factor expression during fracture healing. Primary cilia have been shown to play an indispensable role in
osteoblast differentiation and functions. Recent studies have reported the adverse effect of diabetes on
primary cilia of several organs such as the pancreas and kidney. However, the impact of diabetes on
osteoblast primary cilia during fracture healing and the underlying pathological mechanism have not been
well defined. We previously showed that IFT80 protein is essential for primary cilia formation and
osteoblast differentiation during bone development. Moreover, diabetes upregulates Foxo1 expression,
leading to defective fracture healing. Meanwhile, deletion of Foxo1 in chondrocytes can rescue the effect
of diabetes-induced impaired fracture healing. Thus, this study tested a hypothesis that primary cilia in
osteoblasts are essential for osteogenesis during fracture healing, and diabetes-induced Foxo1
upregulation impairs bone formation through disruption of primary cilia formation in osteoblasts.
Methods
Methods: To test whether diabetes impairs fracture healing through disruption of primary cilia in
osteoblasts, mice with IFT80 deletion in osteoblasts utilizing OSXcretTAIFT80f/f mice model in
normoglycemic and streptozotocin-induced type 1 diabetic mice were created and analyzed. To
investigate if Foxo1 mediates the effect of diabetes on ciliogenesis, mice with Foxo1 deletion in
osteoblasts (OSXcretTAFoxo1f/f) were generated and analyzed in normoglycemic and streptozotocininduced type 1 diabetic mice. OSXcretTA mice (normoglycemic and diabetic) were considered as control in
both studies. A closed femur fracture model was induced in all groups at age 12 weeks old. Femur callus
specimens at day 21 post-fracture were obtained to assess osteoblast ciliogenesis by immunostaining,
bone formation using microCT and histological analysis. Callus specimens at day 35 post-fracture were
used to investigate the mechanical strength of calluses. In-vitroexaminations were performed to explore
ciliogenesis and osteogenesis of primary osteoblasts with IFT80 or Foxo1 deletion exposed to advanced
glycation end products (AGEs) or unmodified BSA (as control). ChIP, gain of function assays and
luciferase activity analysis were carried out to assess if Foxo1 transcriptional factor regulates IFT80 gene
expression. All data are presented as the mean ± standard deviation. Statistical significant was
determined by ANOVA at P
Results
Results: Micro-CT and histological analysis exhibited significantly less bone volume with more porous
woven bone in the fracture callus of diabetic OSXcretTAmice, normoglycemic and diabetic

OSXcretTAIFT80f/fmice compared to normoglycemic control mice (P0.05). Immunofluorescent images
demonstrated a dramatic decrease of cilia number in bone lining cells of fracture callus specimens
obtained from normoglycemic OSXcretTAIFT80f/f, diabetic OSXcretTAand diabetic OSXcretTAIFT80f/fmice
(14%, 9% and 6%, respectively) compared to those from the control mice (51%) (PIn-vitro studies showed
that AGEs treatment and IFT80 deletion significantly reduced cilia number and differentiation of
osteoblasts. Interestingly, the adverse effect of diabetes was reversed in diabetic mice with osteoblastspecific deletion of Foxo1 (diabetic OSXcretTAFoxo1f/f). Micro-CT and histological analysis showed a
significant reduction in the bone volume of diabetic OSXcretTAmice compared to the control mice
(normoglycemic OSXcretTA). However, when Foxo1 was deleted in diabetic mice, the bone volume was
significantly restored (P>0.05). Consistently, the expression of osteoblast markers was dramatically

downregulated in diabetic OSXcretTAmice but restored considerably in diabetic mice with Foxo1 deletion.
Strikingly, diabetes-reduced cilia formation in bone lining cells was rescued in diabetic OSXcretTAFoxo1f/f
mice to a level comparable to control mice (P>0.05). In-vitro, AGEs treatment significantly reduced the
mineralization and ciliogenesis in osteoblasts, which were dramatically reversed by Foxo1 ablation. ChIP
results showed that the interaction between Foxo1 and IFT80 promoter dramatically increased in AGEs
treated osteoblasts compared to the unmodified BSA treated cells, and overexpression of Foxo1 resulted
in 2.2-fold downregulation of IFT80 gene expression level. Furthermore, the IFT80 promoter-driven
luciferase activity was significantly inhibited in osteoblasts treated with AGEs compared to the cells
treated with unmodified BSA.
Conclusions
Conclusions: Our results show that primary cilia in osteoblasts are essential for osteogenesis during
fracture healing. Diabetes-enhanced Foxo1 activity reduced ciliogenesis in osteoblasts resulting in
defective fracture healing. Ablation of Foxo1 rescued diabetes- impaired fracture healing through
restoring ciliogenesis.
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ABSTRACT
Objective: Impaired fracture healing in diabetic patients remains a clinical challenge. Diabetes
adversely affects chondrocytes, osteoblasts and their progenitors through various mechanisms
such as increased inflammatory cytokine expression, enhanced reactive oxygen species
production and reduction in growth factor expression during fracture healing. Primary cilia have
been shown to play an indispensable role in osteoblast differentiation and functions. Recent
studies have reported the adverse effect of diabetes on primary cilia of several organs such as
the pancreas and kidney. However, the impact of diabetes on osteoblast primary cilia during
fracture healing and the underlying pathological mechanism have not been well defined. We
previously showed that IFT80 protein is essential for primary cilia formation and osteoblast
differentiation during bone development. Moreover, diabetes upregulates Foxo1 expression,
leading to defective fracture healing. Meanwhile, deletion of Foxo1 in chondrocytes can rescue
the effect of diabetes-induced impaired fracture healing. Thus, this study tested a hypothesis
that primary cilia in osteoblasts are essential for osteogenesis during fracture healing, and
diabetes-induced Foxo1 upregulation impairs bone formation through disruption of primary cilia
formation in osteoblasts.
Methods: To test whether diabetes impairs fracture healing through disruption of primary cilia
in osteoblasts, mice with IFT80 deletion in osteoblasts utilizing OSXcretTAIFT80f/f mice model in
normoglycemic and streptozotocin-induced type 1 diabetic mice were created and analyzed.
To investigate if Foxo1 mediates the effect of diabetes on ciliogenesis, mice with Foxo1
deletion in osteoblasts (OSXcretTAFoxo1f/f) were generated and analyzed in normoglycemic and
streptozotocin-induced type 1 diabetic mice. OSXcretTA mice (normoglycemic and diabetic) were
considered as control in both studies. A closed femur fracture model was induced in all groups
at age 12 weeks old. Femur callus specimens at day 21 post-fracture were obtained to assess
osteoblast ciliogenesis by immunostaining, bone formation using microCT and histological
analysis. Callus specimens at day 35 post-fracture were used to investigate the mechanical
strength of calluses. In-vitro examinations were performed to explore ciliogenesis and
osteogenesis of primary osteoblasts with IFT80 or Foxo1 deletion exposed to advanced
glycation end products (AGEs) or unmodified BSA (as control). ChIP, gain of function assays
and luciferase activity analysis were carried out to assess if Foxo1 transcriptional factor
regulates IFT80 gene expression. All data are presented as the mean ± standard deviation.
Statistical significant was determined by ANOVA at P<0.05.

VII

Results: Micro-CT and histological analysis exhibited significantly less bone volume with more
porous woven bone in the fracture callus of diabetic OSXcretTA mice, normoglycemic and
diabetic OSXcretTAIFT80f/f mice compared to normoglycemic control mice (P<0.05). However,
the difference among those three groups was not statistically significant (P>0.05).
Immunofluorescent images demonstrated a dramatic decrease of cilia number in bone lining
cells of fracture callus specimens obtained from normoglycemic OSXcretTAIFT80f/f, diabetic
OSXcretTA and diabetic OSXcretTAIFT80f/f mice (14%, 9% and 6%, respectively) compared to
those from the control mice (51%) (P<0.05). In-vitro studies showed that AGEs treatment and
IFT80 deletion significantly reduced cilia number and differentiation of osteoblasts.
Interestingly, the adverse effect of diabetes was reversed in diabetic mice with osteoblastspecific deletion of Foxo1 (diabetic OSXcretTAFoxo1f/f). Micro-CT and histological analysis
showed a significant reduction in the bone volume of diabetic OSXcretTA mice compared to the
control mice (normoglycemic OSXcretTA). However, when Foxo1 was deleted in diabetic mice,
the bone volume was significantly restored (P>0.05). Consistently, the expression of osteoblast
markers was dramatically downregulated in diabetic OSXcretTA mice but restored considerably
in diabetic mice with Foxo1 deletion. Strikingly, diabetes-reduced cilia formation in bone lining
cells was rescued in diabetic OSXcretTAFoxo1f/f mice to a level comparable to control mice
(P>0.05). In-vitro, AGEs treatment significantly reduced the mineralization and ciliogenesis in
osteoblasts, which were dramatically reversed by Foxo1 ablation. ChIP results showed that
the interaction between Foxo1 and IFT80 promoter dramatically increased in AGEs treated
osteoblasts compared to the unmodified BSA treated cells, and overexpression of Foxo1
resulted in 2.2-fold downregulation of IFT80 gene expression level. Furthermore, the IFT80
promoter-driven luciferase activity was significantly inhibited in osteoblasts treated with AGEs
compared to the cells treated with unmodified BSA.
Conclusions: Our results show that primary cilia in osteoblasts are essential for osteogenesis
during fracture healing. Diabetes-enhanced Foxo1 activity reduced ciliogenesis in osteoblasts
resulting in defective fracture healing. Ablation of Foxo1 rescued diabetes- impaired fracture
healing through restoring ciliogenesis.
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Chapter 1
INTRODUCTION
1.1 Physiologic fracture healing
Fracture healing is a well-orchestrated and highly dynamic regenerative process
with coordination of multiple cell types [1–3]. Fracture healing involves a combination of
intramembranous and endochondral bone formation. The intramembranous bone
formation occurs by direct bone formation without using cartilage as a template.
Osteoprogenitor and mesenchymal stem cells (MSCs) on the periosteal and endosteal
surfaces are the primary sources of the cells involved in the intramembranous bone
formation. The endochondral bone formation process involves recruitment, proliferation,
and differentiation of MSCs into chondrocytes to form a soft cartilaginous callus [3–5]. The
majority of MSCs recruited to the fracture site are derived locally from the periosteum and
bone marrow [6]. Cartilaginous callus will eventually calcify and be replaced by bone.
Finally, bone remodeling occurs with osteoclasts resorbing woven bone followed by the
replacement of lamellar bone formation by osteoblasts [3–5]. The fracture healing process
can be divided into four overlapping phases: initial inflammatory phase (day 0-5),
cartilaginous callus formation phase (day 5-16), bony callus formation phase (day 16-21)
and bone remodeling phase (day 21-35) (Figure 1) [3,4,7].
Immediately following the trauma-induced fracture, the blood vessels surrounding the
bone and periosteum rupture, which leads to the formation of hematoma [1,2]. The trauma
also recruits immune cells, including platelets, neutrophils and macrophages. These
immune cells invade the hematoma and secrete growth factors and cytokines, which
initiate the fracture healing cascade [8,9]. Neutrophils remove dead cells and debris, and
secrete proinflammatory cytokines, including tumor necrosis factor- alpha (TNF-α),
interleukin-1 (IL-1), IL-6 and IL-10 to attract monocytes, which will differentiate to
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macrophages [10,11]. Macrophages undergo programming to become classically
activated M1 macrophages or alternatively activated M2 macrophages. M1 macrophages
(inflammatory macrophages) secrete further IL-1, IL-6, TNF-α and monocyte
chemoattractant protein-1 to maintain the recruitment of monocytes and perform
phagocytosis to remove necrotic cells. However, M2 macrophages secrete antiinflammatory cytokines including IL-10, transforming growth factor-beta (TGF-β), bone
morphogenic protein-2 (BMP-2), and vascular endothelial growth factor (VEGF) to recruit
MSCs, enhance angiogenesis and finally promote matrix formation [12–14]. Meanwhile,
platelets secrete platelet-derived growth factor (PDGF) and TGF-β to recruit and promote
MSC differentiation into chondrocytes [9,15].
Chondrocytes will populate in the fracture site and deposit an extra cellular matrix
(ECM) to form soft cartilaginous callus rich in type II collagen and proteoglycans [16,17].
SRY-Box transcription factor 9 (Sox9) expression plays an essential role in the
cartilaginous formation. Sox9, along with transcriptional co-factors Sox5 and Sox6,
regulates the expression of type II collagen and aggrecan [18–20]. Chondrocytes will then
differentiate into a hypertrophic phase characterized by type X collagen expression [1,2].
Later, TNF-α level increases, which initiates the apoptosis of hypertrophic chondrocytes
and the cavities that remain are invaded by blood vessels, facilitating vascular invasion
into the cartilage callus [1,3,21]. Hypertrophic chondrocytes also express the receptor
activator of nuclear factor kappa-B ligand (RANKL) and support osteoclast formation,
leading to further cartilage resorption [22]. Cartilage resorption facilitates the formation
and the invasion of new blood vessels, which enhances the recruitment of osteoblasts and
further migration of MSCs and differentiation to osteoblasts. This leads to callus
mineralization, as osteoblasts use the soft callus as a template to deposit woven bone and
form a hard bony callus [23]. There is another theory for the source of osteoblasts, that
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hypertrophic chondrocytes lose Sox9 expression and subsequently relieve the repression
of osteogenic promoters and begin the expression of bone canonical markers, including
Alkaline phosphatase (ALP), Osterix (OSX), Osteopontin (OPN) and Osteocalcin (OCN)
[24–26].
At the final phase, the hard bony callus undergoes repeated remodeling — termed
“coupled remodeling”. The “coupled remodeling” is a balance of resorption by osteoclasts
and new bone formation by osteoblasts. During this process, the original cortical and
trabecular bone with the medullary cavity is re-established. As a result, the biomechanical
properties are recovered [1,2,27]. During the bone remodeling phase, osteoclast
progenitors are recruited, and mature osteoclasts are formed and resorb the bone.
RANKL, Macrophage Colony Stimulating Factor (M-CSF) and Osteoprotegerin (OPG) are
three key signaling molecules that modulate osteoclast formation, function and survival.
Osteoblasts secrete RANKL in response to proinflammatory cytokines, such as TNF-α, IL1 and M-CSF. RANKL then binds to the RANK receptors on the surface of osteoclasts
and their precursors and facilitates osteoclast formation [28,29]. Once osteoclasts form
and attach to the bone surface, they secrete cathepsin K protease from their ruffled border,
resulting in catabolizing type I collagen, elastin and gelatin [30]. Once collagen fibrils
become exposed during the matrix resorption process, the surface becomes prepared for
bone formation. Osteoclasts release TGF-β and insulin-like growth factor-1 (IGF-1) from
bone matrix to induce osteoblast mediated bone formation. Osteoblasts produce
extracellular proteins first as unmineralized osteoid that subsequently mineralizes through
the accumulation of calcium phosphate in the form of hydroxyapatite. At the end of the
bone formation cycle, the majority of osteoblasts undergo apoptosis process or become
either osteocytes or bone lining cells [31,32].
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Figure 1. Four stages of fracture healing. Fracture healing starts first with inflammation and
hematoma formation followed by cartilaginous soft callus. Soft callus is then replaced by
calcified tissue forming hard bony callus. Finally, the remodeling phase which is the longest
phase of healing happens to restore the bony architecture [7].

1.2 Ciliary structures and functions
Cilia are highly conserved microscopic, hair-like organelles that extend from the
surface of eukaryotic cells. They consist of a microtubule-based axoneme that emanates
from the basal body and is surrounded by the ciliary membrane [33–35]. The ciliary
membrane is continuous with the plasma membrane of the cell body and is open to the
cytoplasm at its base. However, the protein and lipid content within the cilia membrane
differs greatly from the plasma membrane [36]. The axoneme is separated from the cell
body by the transition zone that acts as a ciliary gate that regulates the influx and efflux of
proteins from the cilium. The basal body is composed of a ring of nine triplets of gamma
tubulin that docks at the cell surface and initiates ciliogenesis [37,38]. The presence of
cilia is associated with the cell cycle. Cilia are only assembled when the cell exits the cell
cycle from mitosis into a stationary, quiescent and/or differentiated state; conversely, entry
into the cell cycle is preceded by ciliary resorption (Figure 2). The timing of cilia formation
is limited to these stages of the cell cycle since the cilium nucleates from its base by the
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basal body, which is derived from the mother centriole of the centrosome that docks at the
plasma membrane extending out an axoneme. The centrosome also plays an essential
role in making the mitotic spindle during cell division. As a result, the cilium is resorbed
prior to mitosis to release the centrioles and shortly after mitosis is completed, ciliogenesis
begins [39–41].

Figure 2. Regulation of cilia formation during the
cell cycle. During G1/G0, the primary cilium
assembles as the mother centriole of the
centrosome docks at the plasma membrane.
During S/G2, primary cilium disassembles and
centriole duplicates to form mitotic spindles
during cell division [35].

There are two types of cilia: motile cilia (9+2) and non-motile cilia (9+0), where “9”
refers to the number of outer doublet microtubules present in the ciliary axoneme and “2”
or “0” refers to the number of central microtubules present [42]. Motile cilia are generally
present as multiple cilia on the epithelial surface of specialized cells such as respiratory
tracts, brain ventricles, middle ears and fallopian tubes for fluid movement and the sperm
tail (flagellum) for its movement [42–44]. Motility requires the presence of axonemeassociated inner and outer dynein arms that are attached to the peripheral microtubules
with certain periodicity. Dynein arms generate power for ciliary beat motion. Radial spokes
and central pair projection are additional accessory structures that regulate dyneinmediated motility. In contrast, primary cilia (9+0) are non-motile and lack central
microtubule pairs, axonemal dynein arms and radial spokes (Error! Reference source n
ot found.) [42,45,46]. Primary cilia present as a single cilium at the surface of most
vertebrate cells. They are essential sensory organelles that enable the cells to interact
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and communicate with the surrounding environment to detect changes in the extracellular
environment and transmit signaling information to the cell to control cellular processes
during development and in tissue homeostasis. In bone, primary cilia play an essential
role in differentiation, mechanotransduction and alignment of bone cells [47–49].

Figure 3. Structure of the primary cilium. (A) Schematic longitudinal view of a primary cilium with the
9+0 axoneme extending from the basal body. The ciliary axoneme is surrounded by the ciliary
membrane. (B) Cross-section view of motile cilium and primary cilium. Motile cilium (left) contains
motility-related structures including dynein arms, radial spokes, and a central pair of microtubules.
Primary cilium (right) lacks the motility-related structures. Both primary and motile cilium are bounded
by ciliary membrane and consist of 9 doublet microtubules surrounding [44].

1.3 Ciliary assembly and maintenance
More than 600 proteins reside in the cilium. Some of these proteins are membrane
receptors, such as platelet-derived growth factor receptor, and others are components of
signaling pathways, such as Smoothened (Smo) [50,51]. Cilia lack protein synthesis
machinery, therefore all the proteins that function in cilia need to be transported into the
cilium. Transport of proteins within the cilium is mediated by a specialized transport
system, named intraflagellar transport (IFT), which also plays an essential role in cilia
assembly and function [52,53]. The IFT system was first discovered in the green algae
Chlamydomonas reinhardtii by Kozminski and co‐workers in 1993 [54]. IFT serves as a
two-way transport system along the ciliary axoneme to shuttle proteins from the basal
body to the tip (anterograde transport), mediated by IFT-B complex, and to transport the
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products of axonemal turnover to the cell body (retrograde transport), mediated by IFT-A
complex [52,55,56]. The IFT-B complex is composed of IFT proteins, including
IFT22/25/27/52/70/74/81/88 in the core and IFT172/80/57/20 in the periphery. IFT-A
contains six proteins, including IFT144/140/139/122/121/43 [52,56–59] (Figure 4).
Mutations in the IFT-A proteins complex result in short and wide cilia with bulb-like
structures at their tips [60,61], whereas mutations in IFT-B proteins lead to absent or
severely truncated cilia [62,63].
IFT complex B (IFT-B) is powered by kinesin-2 motor and IFT complex A (IFT-A) is
driven by dynein-2 motor protein [55,56]. Kinesin-2 motor consists of two heterodimerized
kinesin-2 motor subunits (KIF3A and KIF3B) and an accessory subunit, kinesin-associated
protein (KAP) [57]. These motor proteins are essential for the assembly and maintenance
of cilia in which the mutation or deletion of one of the motor subunits inhibits cilia formation
[57,58]. The disruption in dynein-2 motor protein leads to malformed and swollen cilia,
which cannot function properly [64].
In addition to IFT complexes, there is a BBSome complex composed of seven highly
conserved core proteins: BBS1, BBS2, BBS4, BBS5, BBS7, BBS8 and BBS9. BBSome
complex has been indicated in the trafficking of proteins to the cilium in association with
the IFT particles [65,66]. Loss of BBSome components, such as BBS-7 or BBS-8, leads
to the dissociation of the IFT-A and IFT-B subcomplexes [67].
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Figure 4. Schematic of the intraflagellar transport (IFT) system in the primary cilium. Anterograde cytoplasm
transport (from the basal body to the ciliary tip) is mediated by the IFT complex-B proteins attached to the
motor protein kinesin. Retrograde transport (from the ciliary tip to the) depends on the IFT-complex A
proteins attached to dynein motor protein [48].

1.4 Role of primary cilia and IFT80 in the bone
Bone tissue (osseous tissue) is a rigid mineralized connective tissue that exerts
different functions in the body, such as providing mechanical support for the body,
enabling mobility, harboring bone marrow cells, locomotion, storing minerals, such as
calcium, and protecting vital organs from harmful impacts that can result in injury [68–70].
Structurally, bone tissue is mainly composed of inorganic material known as mineralized
matrix (approximately 65%) and an organic ECM. The mineralized matrix primarily
consists of crystalized hydroxyapatite (HA, Ca5(PO4)3OH) and the ECM is mainly
composed

of

type

1

collagen

fibers

and

ground

substance

containing

glycoproteins, proteoglycans, and glycosaminoglycans. The inorganic and organic
materials are structured into two different tissue types: 1) the inner part consists of
trabecular bone (cancellous bone) that has a sponge-like structure, and 2) the outer part
is composed of hard compact bone (cortical bone) [70,71].
Bone tissue is populated by four types of cells: osteoclasts, osteoblasts, osteocytes
and bone lining cells (BLCs) [72] (Figure 5). Osteoclasts are terminally differentiated
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multinucleated cells derived from hematopoietic stem cell lineage and are responsible for
degradation of bone. Osteoclasts contain large quantities of tartrate-resistant acid
phosphatase and hydrolytic enzymes that are involved in the bone resorption process [73].
Osteoblasts are cuboidal cells derived from MSCs, located along the bone surface and
responsible for bone formation [74]. The commitment of MSCs towards the
osteoprogenitor lineage differentiation requires the expression of specific genes, following
the synthesis of BMPs and members of the Wingless (Wnt) pathways [75,76]. The
expression of Runt-related transcription factor-2 (Runx-2) and OSX is crucial for the
osteoblast differentiation [77,78]. Runx-2-null mice develop cartilage with late chondrocyte
maturation but have no osteoblasts [79,80]. Mice with OSX deficiency develop a normalshaped skeleton composed of only cartilage, without osteoblasts or mineralized matrix
[81]. Additionally, Runx-2 has been demonstrated to upregulate osteoblast-related genes,
such as type 1 Collagen (Col-1), ALP, Bone sialoprotein and OCN [82]. At the end of the
bone formation cycle, the majority of osteoblasts enter the apoptosis process [68,83]. The
remaining osteoblasts either entrap in the bone matrix and become osteocytes or cover
the resting bone surface and become BLCs [68,70]. Osteocytes are located within lacunae
surrounded by mineralized bone matrix tissue. Osteocytes possess dendritic morphology,
and their cytoplasmic process crosses the canaliculi to make connection with other
neighboring osteocytes. Osteocytes function as the sensor of mechanical stress, the
regulator of bone formation and resorption, and the reservoir of calcium in bone [84]. BLCs
are quiescent, flat and long-shaped osteoblasts that cover the inactive bone surfaces,
where neither bone resorption nor bone formation occurs. The functions of BLCs are not
fully understood, but it has been shown that BCLs may function in calcium exchange and
mineral homeostasis. They also protect the bone from any osteoclast resorptive activity
when bone resorption should not occur, such as osteoporosis [85]. Moreover, BLCs
remove the remaining collagen fibers prior to bone formation [86]. It has also been
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suggested that BLCs constitute part of the osteoblast lineage cells with the capacity to
activate into osteoblasts. Compared to osteoblasts, BLCs show different gene expression
profiles including increased expression of Mmp13, M-CSF and RANKL [87]. Interestingly,
BLCs produce RANKL and promote osteoclastogenesis in response to orthodontic force
and estrogen deficiency [88,89].
In addition to bone cells, bone tissue contains blood vessels and nerves. The majority
of nerves in bone are found along blood vessels [90]. In close contact with endothelia
cells, there are stellate-shaped cells named pericytes. Pericytes are mesenchymal
cells that have been shown to be a source of osteogenic cells in bone fracture healing
[91,92]. Leukocytes, red blood cells, platelets, adipocyte and stem cells also present in
the bone marrow [93].

Figure 5. The bone remodeling cycle and differentiation of bone cells. Osteoclasts originate from
hematopoietic stem cells (HSC). Osteoclasts attach to the bone surface and create acidic environment
to resorb the bone. Monocytes or macrophages remove debris. Then osteoblasts produce osteoid
matrix which will mineralize [72].

The first evidence of primary cilia in the skeleton was the discovery of cilia on
chondrocytes about 50 years ago [94]. Cilia are also present in osteoprogenitors,
osteoblasts, osteocytes, BLCs, pre-osteoblasts MC3T3-E1 cell-line and MLO-Y4 line [95–
10

98]. Primary cilia and IFT proteins are extensively reported to be essential for regulating
osteogenesis in bone development [47,48]. Defects of cilia and/or IFT proteins result in
severe skeletal abnormalities such as Ellis–van Creveld syndrome, Sensenbrenner
syndrome and short-rib polydactyly syndromes, showing short limbs, thoracic hypoplasia
with respiratory failure and polydactyly, which further highlights the significant role of
primary cilia in bone development [99,100]. The IFT proteins have been shown to be
essential for cilia formation and function of osteoblasts [48]. For example, conditional
deletion of KIF3A in osteoblasts using KIF3AOcn-KO mice model results in a significant
reduction in ciliogenesis and knockout (KO) mice demonstrate dramatic bone loss with
osteoporosis phenotype [101]. Besides the role of primary cilia in differentiation, primary
cilia are needed for the osteoblast alignment [49]. The alignment, polarization, and
interaction of osteoblasts are crucial for the formation of bone matrix [102]. Ablation of
IFT20 in osteoblast precursor cells (OPCs) results in disorganized collagen fibrils,
compromised osteoblast/osteocyte alignment and loss of osteoblast apicobasal polarity
in-vitro and in-vivo. Mechanistically, IFT20 interacts with the ceramide- PKCζ complex
(protein kinase C, zeta) to promote PKCζ phosphorylation in cilia and induce the apical
localization of β-catenin in osteoblasts. Deletion of IFT20 disrupts ceramide-pPKCζ-βcatenin signaling axis, leading to the disruption of the cell alignment of osteoblasts and
ultimately reduced bone strength and stiffness. These results indicate that IFT20 in the
primary cilia is important for the apicobasal polarity of the osteoblasts [49]. More studies
have investigated the impact of different IFT proteins deletion on bone development, which
has been summarized in Table 1.
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Table 1. Summary of the studies regarding the role of primary cilia and IFT proteins on bone.
Bone phenotypes

Ciliary genes
IFT20

IFT88

IFT144

IFT140

KIF3A

Ablation of IFT20 in craniofacial osteoblasts disrupts collagen biosynthesis
leading to craniofacial bone defects. Wnt1-Cre;IFT20f/f mice demonstrate
hypertelorism, frontonasal dysplasia with an opening in the metopic suture,
abnormal expansion of the facial midline, absence of the palatal process of
the palatine and pterygoid bone. The maxillary and mandibular bones and
palatal process of the maxilla in IFT20 KO mice are hypoplastic.
Wnt1-Cre;IFT88f/f mice have disrupted ciliogenesis and reduced neural
crest cell proliferation in the palatal shelf resulting in severe craniofacial
defects including bilateral cleft lip and palate and tongue agenesis.
Maxillary process of Wnt1-Cre;IFT88f/f mice shows ectopic excess bone
formation in the maxillary process and ectopic apoptosis in the maxillary
process at an early stage of development. Mandibular bone of Wnt1Cre;IFT88f/f mice is slightly shortened with ectopic bone formation due to
the cilia loss-mediated disruption of Hh signaling.
Disruption of cilia formation by deletion of IFT88 in osteochondroprogenitors
cells nearly abrogates the increased osteogenesis response to fluid shear
stress demonstrating the significance of primary cilium in
osteochondroprogenitors in responding to mechanical stimulus.
Deletion of IFT88 in osteoblasts abolishes the pulsed electromagnetic field
-induced up-regulation of BMPRII and its ciliary localization and
subsequent activation of BMP-Smad1/5/8 signaling.
Mutations in IFT144 gene cause sever skeletal defects such as
polydactyly, short ribs, small rib cage, short limbs and craniofacial
anomalies. Mutation of IFT144 exhibits ligand-independent expansion of
Hh signaling and defects in Shh/GREM1/FGF interactions, particularly in
the limbs and facial prominences
IFT40 highly expresses in bone during bone development. IFT40
expression downregulates in the long bones of murine osteoporosis
models (aging- and ovariectomy). Osx-Cre;IFT140f/f mice show dwarf
phenotypes, such as short bone length, significant decrease in trabecular
bone mass/mineralization, with narrow and disorganized growth plate.
KIF3AOc-cKOmice exhibit dramatic reduction in bone volume and cortical
thickness with impaired osteoblast function. Deletion of KIF3A in
osteoblasts inhibits osteoblast differentiation through blocking intracellular
calcium response and disruption of Wnt and Hh signaling pathways.
Colα1(I) 2.3–Cre;Kif3af/f mice don’t show skeletal abnormalities but
decrease new bone formation in response to a cyclic ulnar loading.
Knockdown of Kif3a suppresses osteoblastic differentiation in human
dental follicle cells and human dental pulp cells via disruption in Wnt
signaling pathway.
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Among various components of the IFT system, IFT80 -a component of complex B
component- has been shown to be highly expressed in osteoblast progenitor cells,
osteoblasts, and bone [47,114,115]. The significance of IFT80 in bone was brought to
attention as two studies showed the mutation of IFT80 in human Jeune asphyxiating
thoracic dystrophy (JATD) and short rib polydactyly (SRP) syndromes, which both
diseases manifest severe bone abnormalities. [116,117]. Beales et al. found mutation in
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IFT80 in families with JATD in 2007. They also showed that the loss of IFT80 leads to a
total loss of ciliation in the Tetrahymena [116]. Moreover, Zebrafishes lacking IFT80
function using morpholinos have reduced number of and decreased length of cilia [118].
In addition, Cavalcanti found mutations in IFT80 in fetuses with a lethal form of SRP in
2011 [117]. The first murine model for IFT80 was generated by Rix and colleagues in
2011. They generated Ift80gt/gt (gene-trap line) mice which is a hypomorphic model. The
majority of the Ift80gt/gt mice died during embryonic development and the remainder of the
mice (2%) that survived to the postnatal stages exhibited the JATD and SRP type III
phenotypes, including growth retardation, shortening of the long bones, ribcage
constriction and polydactyly. Moreover, Hh (hedgehog) signaling was disrupted in the
IFT80gt/gt mouse embryonic fibroblasts. However, the role of IFT80 in osteoblast
differentiation and function is still unclear due to the mouse embryonic lethality [119].
Our laboratory focuses on investigating the role of IFT80 in bone cells. Our previous
studies showed that IFT80 is essential in osteoblast differentiation by regulating Hh–Gli
(hedgehog–glioma-associated oncogene) signal pathways [115,120]. Silencing IFT80 in
murine mesenchymal progenitor cell line (C3H10T1/2) and bone marrow-derived stromal
cells disrupts cilia formation and blocks osteoblast differentiation. Silencing IFT80 also
inhibits Gli2 expression which is a critical transcriptional factor involved in the Hh signaling
pathway and facilitating the expression of osteoblast markers. Gli2 overexpression
rescues the disrupted osteoblast differentiation in IFT80-silenced cells. Additionally,
treatment of IFT80-silenced cells with Smo agonist promotes osteoblast differentiation
[115]. These results showed that IFT80 is essential for osteoblast ciliogenesis and
differentiation. To further study the role of IFT80 in osteoblast function, our laboratory
generated a conditional knockout mouse model of IFT80 flox/flox (IFT80f/f) and
deleted IFT80 in the osteoblast lineage with Osx-Cre [121]. The Osx-cre;IFT80f/f mice
model displays a significant growth retardation and osteopenia phenotype. Deletion of
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IFT80 in OPCs disrupts cilia formation, impairs osteoblast differentiation and blocks
canonical Hh-Gli signaling transduction. Interestingly, loss of IFT80 stimulates ciliaindependent non-canonical Hh-Gαi-RhoA (Ras homolog family member A) signaling,
resulting in excess stress fibers and further inhibition in osteoblast differentiation. Inhibition
of RhoA or actin stress fiber promotes ciliogenesis and restores osteoblast differentiation
of IFT80-deleted OPCs. Therefore, IFT80 plays a crucial role in regulating osteoblast
differentiation by balancing canonical Hh-Gli and noncanonical Hh-Gαi-RhoA pathways
[121].
The role of IFT80 has also been noted in other types of cells. IFT80 expression
upregulates in dental pulp stem cells during tooth development. Deletion of IFT80 in dental
pulp stem cells inhibits odontogenic differentiation by disrupting cilia formation and
inhibiting fibroblast growth factor (FGF) receptor expression, FGF signaling, Hh signaling
and their crosstalk [122]. Mice with deletion of IFT80 in odontoblasts exhibit reduced
dental pulp stem cell proliferation in the cervical loop and impaired molar root
development, with shorter molar roots, less mineralized dentin and delayed incisor
eruption [123]. IFT80 also has a crucial role in chondrocyte ciliogenesis and function. Mice
with deletion of IFT80 in chondrocytes at embryonic stage (Col2α1-Cre;IFT80f/f) manifest
disrupted cartilage development and shortened limbs at birth. Deletion of IFT80 at the
postnatal phase (Col2α1-CreERT;IFT80f/f) dramatically decreased the growth plate length
but increased articular cartilage thickness. Mechanistically, deletion of IFT80 in
chondrocytes disrupts cilia formation in cartilage resulting in altered Hh and Wnt signaling
and eventually blocks chondrocyte differentiation [124]. In addition, the Col2CreER;IFT80f/f mouse model has an early onset of intervertebral disc degeneration with
disrupted intervertebral disc structure; disorganized and reduced growth plates and
endplates due to increased chondrocyte apoptosis, and decreased chondrocyte
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differentiation and function [125]. All these studies shed light on the indispensable role of
IFT80 in cilia formation, and function of bone and craniofacial cells.
Besides the role of IFT80 and primary cilia in bone development, our laboratory has
further studied the role of IFT80 in fracture healing. We found that IFT80 expression is
highly upregulated during fracture healing. Fracture calluses of Col2α1-CreERT;IFT80f/f
showed a clear decrease in callus size with less bone and cartilage formation [126]. IFT80
deletion in chondrocytes downregulates the expression of angiogenic factors, including
VEGF,

PDGF

and

angiopoietin,

and

inhibits

fracture

callus

vascularization.

Mechanistically, loss of IFT80 in chondrocytes dramatically reduces chondrocyte
proliferation, cilia assembly and chondrogenic gene expression and differentiation by
downregulating the expression of TGF-β receptors and the phosphorylation of Smad2/3
in the fracture callus [126]. Despite the progress in understanding the role of IFT80 in
primary cilia and functions of different cell types, the impact of IFT80 and primary cilia in
osteoblasts during fracture healing has not been investigated.

1.5 Diabetes, fracture and primary cilia
Diabetes mellitus (DM) is a chronic disorder characterized by chronic elevated blood
glucose due to defects in the metabolism of carbohydrate, fat and protein [127,128]. DM
is one of the leading causes of mortality in the world and as of 2015, more than 415 million
adults have DM, with this number projected to increase to 642 million by 2040 [129]. There
are two major types of diabetes: type 1 DM (T1DM) and type 2 (T2DM). T1DM is an
autoimmune disease characterized by the chronic inflammation of the pancreatic islets of
Langerhans. Islet inflammation is typically marked by infiltrating adaptive and innate
immune cells resulting in destruction of beta-cells, insulin deficiency and hyperglycemia
[130–132]. T2DM is more frequent than T1DM and is characterized by peripheral insulin
resistance. To compete with the body’s insulin resistance, beta-cells will increase insulin
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production. This aberrant production of insulin leads to increase in pancreatic beta-cells
in the early onset of T2DM thus patients do not develop diabetes symptoms. However, the
beta-cells mass will undergo apoptosis overtime, leading to reduction in insulin production
and the development of hyperglycemia combined with the insulin resistance [133–135].

Diabetes can cause numerous complications such as cardiovascular diseases,
retinopathy, kidney damage, neuropathy, periodontal disease and delayed wound healing
[136]. In addition, patients with diabetes have an increased risk of bone fracture and
complications, such as delayed union and non-union fracture healing [137,138]. A metaanalysis by Vestergaard showed that patients with T1DM and T2DM have 6.9 and 1.3
relative risk of hip fracture, respectively [139]. Hernandez found an increased risk of short
and long bone fracture in patients with T1DM and T2DM [140]. Moreover, a prospective
study reported that the relative risk of hip fracture incidence in patients with T1DM was 6.4
and with T2DM was 2.2 compared with individuals without diabetes [141].

One of the major causes of diabetic complications such as increased risk of fracture
in individuals with T1DM and T2DM, is the formation of advanced glycation end products
(AGEs). The high glucose level leads to covalent bonds with collagen and plasma proteins
through a non-enzymatic process known as glycation. Glycation of proteins and
accumulation of AGEs disrupt their molecular structure, alters their enzymatic activity and
decreases their degradation capacity. Furthermore, AGEs increase the production of
reactive oxygen species (ROS), activate NADPH oxidase and upregulate inflammation
with prolonged cellular dysfunction and localized tissue destruction [142–145]. Interaction
of AGEs with their receptor named RAGE (receptor for advanced glycation end products)
results in alteration of intracellular signaling, gene expression and release of proinflammatory molecules that induce tissue damage [146–149]. The RAGE signaling
pathway can initiate a group of proinflammatory ligands. Sustained RAGE cell expression
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in proximity to AGEs leads to chronic activation of inflammation and tissue damage.
Inflammatory cytokines that are upregulated through AGE-RAGE interaction include TNFα, IL-1, IL-6 and C-reactive protein (CRP) [145,150–152]. As the content of AGEs
increases during diabetes, the cross-linking and modification of bone proteins will extend
resulting in functional alterations of bone cells, such as osteoblasts, which explains the
deleterious effects of diabetes on bone healing. AGEs have been shown to induce
osteoblast functional impairment and inhibit proliferation and differentiation. Increased
concertation of AGEs in cortical and trabecular bone impairs bone density and
mineralization, alters the mechanical properties of bone and disrupts bone remodeling,
resulting in bone fragility and osteoporosis in diabetes [151,153–156]. Increased oxidative
stress induced by AGEs and hyperglycemia also increases RANKL expression, which
simulates osteoclast formation, enhances bone resorption and disturbs bone remodeling
[157–159]. This decline in bone integrity and function in diabetes is associated with
increasing risk of fracture and complications.

Despite these various mechanisms associated with diabetes-impaired fracture
healing, no studies have investigated the interference of diabetes with fracture healing is
linked to the ciliogenesis. Recently, the role of primary cilia in increasing diabetes
susceptibility has been revealed. Gerdes et al. showed that insulin receptor recruits to the
cilium of insulin-stimulated beta-cells and the ciliary/basal body integrity is essential to
activate the insulin signaling pathway. Bardet-Biedl-Syndrome 4 (BBS4) mutant
mice display ciliary/basal body defects with impairment in the insulin signaling pathway,
which leads to significantly poor glucose handling with a delay in glucose clearance
compared with controls. In addition, the pancreas from the diabetes-prone Goto-Kakizaki
rat has less ciliated β-cells with misregulation of ciliary/basal body genes [160]. Pancreatic
islets of diabetes-prone NZO (New Zealand Obese) mice have less ciliated cells and a
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significant downregulation of ciliary genes compared with pancreatic islets of diabetesresistant B6-ob/ob mice. Interestingly, B6-ob/ob islets exhibit an adaptive response to a
carbohydrate diet by significant increases in beta-cell proliferation, whereas NZO islets
lack such an adaptive response. This adaptive proliferation response dramatically
decreases by suppression of the KIF3A gene which is an essential gene for ciliogenesis
[161]. Our laboratory has recently found that diabetes disrupts primary cilia formation in
chondrocytes, resulting in impaired fracture healing with significant reduction in the
cartilaginous callus formation. Although it is well document that diabetes adversely affects
osteoblasts and their progenitors [151,153,154,156], and primary cilia have been shown
to play an indispensable role in osteoblast functions [47–49], it is unknown whether
diabetes impairs osteogenesis during fracture healing through its impact on primary cilia
in osteoblasts.

1.6 Streptozotocin-induced diabetes fracture model
T2DM is much more common than T1DM. T2DM is a complex metabolic disease with
both genetic and environmental factors contributing to the establishment of the disorder.
This makes the animal models representing T2DM more challenging, and they can only
depict a few of the phenotypes of T2DM diseases [162,163]. Nevertheless, it is well known
that both T1DM and T2DM are associated with the increased risk of fracture and
associated complications. However, individuals with T1DM have significantly higher risk
of fracture compared to individuals with T2DM, which represents a serious health issue
[61–63]. So far, the insulin-deficient streptozotocin (STZ) model is one of the most
extensively used T1DM models in various animal species due to the simplicity and
reproducibility of the model [166,167]. The STZ-induced diabetic model has many
similarities with T1DM complications in humans such as chronic hyperglycemia, impaired
bone quality and reduced bone strength [166,168,169].
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STZ was first isolated from soil microorganism Streptomyces achromogenes in 1960
and showed a broad spectrum of antibiotic activity [170]. The diabetogenic property of
STZ was first described by Rakieten in 1963 [171] and its mechanism of action was
identified by Junod et al. in 1969 [172]. STZ (2-deoxy-2-(3-methyl-3-nitrosourea)-1-Dglucopyranose) is a structural analogue of glucose and N-acetyl glucosamine. It
resembles glucose in structure but with a replacement C2 position with an N-methyl-Nnitrosourea group [173] (Figure 6). This structure of STZ facilitates STZ transport into betacells via glucose transport protein GLUT2, which is abundant on beta-cell plasma
membranes [166,174]. Accumulation of STZ in beta-cells causes cellular toxicity and local
immune responses through different mechanisms: 1) methylation of DNA causing DNA
fragmentation, 2) generation of superoxide radicals such as hydrogen peroxide and
hydroxyl radicals and 3) production of nitric oxide which inhibits aconitase activity, leading
to

DNA

alkylation

and

damage

[166,175,176].

Beta-cell

destruction

causes

hypoinsulinemia and hyperglycemia. Hyperglycemia exacerbates AGEs formation,
leading to significant increase in AGEs levels in the STZ-diabetic animal model [177–179].
AGEs have been reported to be closely associated with poor bone quality and bone
fragility in the STZ-induced diabetic mice model [179].

Figure 6. The structure of Glucose, N-acetyl-DGlucosamine, Streptozotocin and N-methyl-Nnitrosourea [173].
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STZ-induced hyperglycemia downregulates bone marker genes including Runx-2,
Osx, ALP, Col-1, dentin matrix acidic phosphoprotein 1 and OC in the murine distraction
osteogenesis model [180]. The Wnt pathway, which is essential for osteoblast
differentiation and regulation of bone formation, dramatically decreases in the bone of
STZ-induced diabetic animals, through the increased expression of Wnt signaling
inhibitors [181]. Moreover, the femur and tibia of the STZ-induced diabetic rats have a
dramatic decrease in biomechanical integrity. Measurements at the break point using a
three-point bending assay revealed that the bones of diabetic rats bore significantly less
load, deformation and energy absorption capacity than controls [169]. STZ-induced
diabetic mice display significant impairment in fracture healing. Femoral fracture calluses
of STZ-induced diabetic mice has a significant increase in TNF-α level, which decreases
the MSCs proliferation and increases MSCs apoptosis in the callus area [182]. TNF-α
overexpression also enhances chondrocyte apoptosis and RANKL expression and
subsequently osteoclast formation, which accelerates cartilage loss in STZ-induced
diabetic animals [183,184]. TNF-α upregulation also increases osteoblast apoptosis and
decreases osteoblast differentiation [185,186]. STZ-induced diabetic mice show a
dramatic reduction in the fracture callus mechanical strength as the callus of diabetic mice
showed 69%, 56%, 74% and 60% reduction in maximum torque, stiffness, toughness and
shear modulus, respectively [187].

1.7 Foxo1 regulation in diabetic fracture healing
Extensive studies have linked the forkhead box O1 (Foxo1) transcription factor
overactivation with diabetic complications [188–190]. The forkhead box, or Fox, gene
family are evolutionary conserved transcriptional factors, first discovered in 1989
in Drosophila melanogaster [191]. To date, 50 Fox genes in the human genome and 44 in
the mouse genome have been identified, and are divided into 19 subfamilies [192]. Foxo
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is one of these subfamily members and includes Foxo1 (or FKHR), Foxo3 (or FKHRL1),
Foxo4 (also called AFX) and Foxo6 [193]. The four members of Foxo proteins share four
sequence homologies, including the forkhead domain, nuclear localization, nuclear export,
and a transactivation domain. Foxos act as transcription factors and their activity can be
regulated by post-translational modifications such as phosphorylation, ubiquitination,
acetylation and methylation [188,194,195]. These post-translational modifications alter the
nuclear localization of Foxos, modify the DNA binding affinity of Foxos and alter
transcriptional activity for Foxos specific target genes. Therefore, Foxo transcriptional
factors regulate multiple cell activities, such as cell cycle, oxidative stress resistance, cell
survival, cellular differentiation, apoptosis, inflammation, energy metabolism and aging
[188,196–198]. Among the four members of the Foxo family, Foxo1, Foxo 3 and Foxo 4
are expressed in bone cells [199] with Foxo 1 the most studied and abundant Foxo
member in the bone [188,200–202].

Foxo1 plays an indispensable role in regulating mesenchymal cell differentiation into
osteoblasts [203]. In mouse embryonic mesenchymal cells (C3H10T1/2 cells), Foxo1
expression dramatically increases during osteogenic differentiation, and silencing Foxo1
inhibits the osteogenic expression resulting in decreased mineralization. Foxo1 interacts
with the Runx-2 promoter and enhances the expression of osteoblast markers during
osteogenesis [202]. Silencing Foxo1 expression in collagen1a1 cells decreases the
osteoblast numbers and leads to defective skeletal and craniofacial development due to
increased oxidative stress [202]. In addition, Foxo1 interacts with ALP promoter and
stimulates the expression of ALP, which is an essential marker for osteoblast maturation
and bone mineralization [204].

The indispensable role of Foxo1 in promoting osteoblast differentiation has also been
revealed in murine pre-osteoblast cell lines (MC3T3-E1). Knockdown of Foxo1 in MC3T321

E1 cell lines using small inhibitory RNA (siRNA) dramatically reduced the expression of
osteoblast markers, including collagen 1, RUNX2, osteocalcin and MMP13. This study
also verifies that Foxo1 transcriptional factor directly interacts with Runx2 promotor during
osteoblast differentiation [205]. Additionally, Foxo1 protects osteoblasts from oxidative
stress through interaction with ATF4 (activating transcription factor 4) — a transcription
factor promoting amino acid import and collagen synthesis in osteoblasts- as well as
through its regulation of a stress-dependent pathway influencing p53 signaling [200].
Moreover, Foxo1 regulates the amount of cartilage produced during fracture healing.
Foxo1 limits excessive cartilage formation at early phases of fracture healing by regulating
chondrocyte proliferation and expression of cartilage matrix genes expression. At later
phases, Foxo1 prevents rapid cartilage loss by regulating IL-6 expression, osteoclast
formation, and the formation of M2-like macrophages [206]. Moreover, Foxo1 regulates
angiogenesis during fracture healing by interacting with the VEGF promoter and inducing
VEGF transcriptional activity in chondrocytes [207].

While Foxo1 is critical in bone development and fracture healing, Foxo1 plays a
negative role in pathologic conditions, such as diabetes [208]. In diabetes, where
inflammation is elevated, Foxo1 activation is dramatically upregulated, which shifts the
binding of Foxo1 to pro-inflammatory promoters. In diabetic callus, Foxo1 interacts with
the TNF-α promoter and enhances the expression of TNF-α, leading to increased
osteoclast formation and premature loss of cartilage. Knockdown of Foxo1 dramatically
reduces the diabetes-induced bone resorptive factors, such as TNF-α, IL-6, RANKL and
MCSF [183]. Foxo1 also increases RANKL expression, causing a dramatic increase in
osteoclast formation in diabetic fracture callus. Both of these parameters are rescued by
Foxo1 deletion in chondrocytes using Col2α1Cre+;Foxo1L/L mice model. In in-vitro studies,
high glucose (HG) and AGEs simulate Foxo1 association with the RANKL promoter and
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increase RANKL promoter activity [209]. Deletion of Foxo1/3/4 in osteoblasts has also
been shown to ameliorate diabetes-induced low bone mass during development by
preventing the reduction in OPG and increased osteoclast numbers [210].
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Chapter 2
SPECIFIC AIMS
T1DM-associated inflammation and hyperglycemia adversely affect osteoblasts and
their progenitor cells, contributing to higher rates of osteopenia and impaired fracture
healing [211,212]. Understanding the underlying mechanism responsible for defective
bone repair in diabetic fracture healing is imperative for developing new and effective
therapeutic strategies.
The primary cilium is a membrane-bound “hair-like” cellular organelle that plays a
critical role in osteoblast differentiation, proliferation, and function during bone
development [33,34,213]. Construction and function of primary cilia require an effective
intraflagellar transport (IFT) system operated by IFT protein complexes and IFT motors.
IFT serves as a two-way transport system along the ciliary axoneme to shuttle proteins
[52,53]. One of the core transport proteins in the IFT system is IFT80. Our laboratory has
identified that IFT80 plays a crucial role in the ciliogenesis and function of osteoblast
precursor cells [115,121]. We also showed that IFT80 deletion in chondrocytes causes
cilia loss and impairs fracture healing [126]. Although the adverse effect of T1DM on
osteoblasts and their progenitor cells has been extensively studied [211,212], whether
TIDM impairs fracture healing through its impact on primary cilia and IFT80 protein is
unknown. Moreover, diabetes-induced defective fracture healing has extensively been
associated with upregulation of Foxo1 transcriptional factor [183,184,209]. In-vivo deletion
of Foxo1 in osteoblast lineage progenitors has been shown to abrogate the loss of
cancellous bone mass in T1DM mouse model [210]. So far, whether diabetes-induced
Foxo1 upregulation inhibits IFT80 gene expression and reduces ciliogenesis in
osteoblasts has not been investigated. Based on the findings that IFT80 and primary cilia
in osteoblasts play a critical role in bone formation as well as diabetes induced Foxo1
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upregulation impairs bone formation, we tested the hypothesis that IFT80 and primary
cilia are essential for osteogenesis during fracture healing and diabetes
upregulates Foxo1 expression, which disrupts ciliogenesis and subsequently bone
formation during fracture healing (Figure 7). To investigate this hypothesis, we deleted
IFT80 in osteoblasts using OsxcretTA to block cilia formation and created a STZ-induced
diabetes model to assess whether impaired fracture healing in diabetic mice is due to the
disruption of ciliogensis in osteoblasts. We also created OsxcretTAFoxo1f/f and
OsxcretTAIFT80f/fFoxo1f/f mouse models to delete Foxo1 or double deletion of Foxo1 and
IFT80 in osteoblasts and determined if ablation of Foxo1 in osteoblasts under diabetic
condition and/or in OsxcretTAIFT80flf can reverse the negative effect of diabetes on cilia
formation and fracture healing.
.

Figure 7. Hypothesized model. The model summarizes the hypothesis that diabetes upregulates Foxo1
expression and increases Foxo1 nuclear translocation resulting in inhibition of IFT80 gene expression and
disruption of primary cilia (an essential organelle in osteoblast differentiation and function).
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Chapter 3
MATERIALS AND METHODS
3.1 Animal models:
All animal experiments were approved by the University of Pennsylvania Institutional
Animal Care and Use Committee. Cre/LoxP recombination system was used to produce
mice with IFT80 gene and Foxo1 gene deletion. In this system, Cre recombinase under
specific

promoter

regulation

recognizes

specific

DNA

fragment

sequences

called loxP (locus of x-over, P1) site and excises DNA sequences between two loxP sites
[214]. To produce primary cilia knockout model, we created IFT80 flox/flox (IFT80f/f) mice
model in which exon 6 in the IFT80 genomic sequence is flanked by two loxP sites. To
specifically delete IFT80 in the osteoblast lineage cells, IFT80f/f mice were crossed with
OsxcretTA transgenic mice (obtained from the Jackson laboratory), which mainly targets
osteoblast precursor cells (OPCs). Foxo1f/f mouse was provided by Dr. Graves’ laboratory
and crossed with OsxcretTA transgenic mice (obtained from the Jackson laboratory) to
produce OsxcretTAFoxo1f/f mice.
OsxcretTAIFT80f/fFoxo1f/f was also produced by crossing IFT80f/fFoxo1f/f mice which
was created by the senior laboratory member Dr. Min Liu, with OsxcretTAFoxo1f/f mice.
Standard breeding schemes (crossing OsxcretTAIFT80f/f mice with IFT80f/f mice, crossing
OsxcretTAFoxo1f/f mice with Foxo1f/f mice and crossing OsxcretTAIFT80f/fFoxo1f/f with
IFT80f/fFoxo1f/f) were used to produce experimental OsxcretTAIFT80f/f, OsxcretTAFoxo1f/f and
OsxcretTAIFT80f/fFoxo1f/f knockout mice model.
Since the OsxcretTA mice display skeletal defect [215], we bred OsxcretTA mice with
C57BL/6 mice and used mice expressing Cre based on the genotyping as control.
Moreover, OsxcretTA mediated recombination contains a reverse tetracycline-dependent
transactivator (rtTA), which the Cre expression is prevented with the administration of
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tetracycline (or its more stable derivative, doxycycline) and initiated when its
administration is stopped [216].

We gave water containing 2 mg/ml doxycycline to

pregnant female mice and their offspring to block Cre expression during skeletal
development. Doxycycline was then withdrawn to let Cre recombinase become expressed
in Osx+ cells right after fracture (12-14-week old), and normal drinking water was provided
for the rest of the study. The OsxcretTA control mice were also bred and raised with drinking
water containing doxycycline until inducing fracture model to prevent Cre-mediated gene
recombination during the skeletal maturation period. Mice were kept under standard
conditions with 12-h light/12-h dark cycle.
The mice genotyping was confirmed by PCR analysis of DNA obtained from a toe
biopsy using Cre, IFT80 and Foxo1 primers. The IFT80 genotyping primers were IFT80F
(5′-TGTGAGGCCAGCCCGAGTTA-3′)

and

IFT80R

(5′-

GCCTGAGCTACAGAGAGACCCCACG-3′) and Foxo1 genotyping primers were Foxo1F
(5′-ACCACTCTGGACGGCATACT-3′) and Foxo1R (5′-TGAGTCTGGGGCTAGTTTGA 3′).

The

Cre

transgene

was

detected

CCTGGAAAATGCTTCTGTCCGTTTGCC-3′)

using
and

two

primers:
CreR

CreF

(5′
(5′

GGCGCGGCAACACCATTTTT-3′).

3.2 Induction of T1DM mouse model:
T1DM was induced in OsxcretTA and OsxcretTAIFT80f/f mice at 9-10 weeks of age by
intraperitoneal injections of streptozotocin (STZ, 40 mg/kg, Sigma-Aldrich, St. Louis, MO)
dissolved in 10 mM sodium citrate buffer (PH = 4.5) once per day for five consecutive days
[189,217]. Control mice received only vehicle (sodium citrate buffer). Blood glucose levels
were measured weekly, starting one week after the last injection. Mice were considered
diabetic when blood glucose levels exceeded 220 mg/dl for two consecutive
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measurements. A fracture model was performed when mice were hyperglycemic for at
least three weeks.

3.3 Murine closed femoral fracture model:
Mice were anesthetized by Isoflurane inhalation (1-4%) and by subcutaneous
application of Bupivacaine (2 mg/kg) prior to the femur fracture surgery. The left leg was
scrubbed with a 10% povidone-iodine then an incision was made lateral to the knee and
the tendon for the quadriceps femoris muscle was pushed laterally to expose the femoral
head. A 27-gauge needle was used to access the femoral bone marrow channel and
inserted a 0.01 stainless steel pin (Azdent) for fixation. After suturing the incision, a uniform
transverse fracture was created in the middle of the femur with internal pin by a threepoint blunt guillotine apparatus [187,209]. The doxycycline water was then removed, and
mice were granted free access to food and water after recovery from anesthesia. The
fracture femur calluses were harvested on Day (D) 21 and D35 following fracture surgery
to assess the primary bone formation and bone remodeling phases, respectively. The
fracture sites were evaluated radiographically and the fracture femur specimens that were
grossly at the end were excluded from the study. An illustration of the study design is
shown in Figure 8.

Figure 8. Schematic figure illustrating experimental design.
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3.4 Micro-computed tomography and image analysis:
To evaluate bone microarchitecture of the fractured femur samples, fractured femurs
specimens from D21 post-fracture were scanned using the μCT 35 system (Scanco
Medical AG, Bassersdorf, Switzerland) with a 10-μm nominal voxel size at the Micro-CT
Imaging Core Facility, McKay Orthopaedic Research Laboratory, Perelman School of
Medicine, University of Pennsylvania. Scan settings were 70 kVp, 114 mA with 200-ms
integration time. The scan area was manually adjusted on 2D CT images to include only
the callus zone and the original cortical bone tissue and the medullary canal were
excluded from evaluation according to previous reports [218–220]. A fixed threshold of
333 mg hydroxyapatite (HA)/cm was then applied for all the samples to evaluate the bone
tissue in the callus. After segmentation, the ratio of the bone volume to the total volume
(BV/TV) and connectivity density (Conn-Dens) were analyzed (200 slices). 3D images
were reconstructed at the fracture line extending at least 3 mm to the proximal and distal.

3.5 Histological analysis:
Fracture femur specimens from D21 were fixed in cold 4% paraformaldehyde
overnight and decalcified for eight weeks with 10% EDTA (pH 7.4) at 4°C. After the
decalcifying process, the samples were soaked in 20% sucrose overnight and then
embedded in optimum cutting temperature (O.C.T.). 8-μm Longitudinal frozen sections
were obtained from the mid-portion of the callus and collected on charged glass slides
(Globe Scientific Inc.) for histology and immunofluorescent measurements. Safranin O
staining was performed to visualize bone. Sections were hydrated in graded ethanol series
(from 100% to 80% for 5 minutes each) and then washed with PBS three times (5 minutes
each) to remove OCT. Sections were stained with 0.05% fast green solution for 5 minutes,
rinsed quickly with 1% acetic acid solution, and then stained with 0.1% Safranin O solution
for 5 minutes. Slides were mounted with Premount mounting media (Fisher scientific,
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SP15100). Quantification of bone area was performed with Image J software. The total
callus volume (TV) was defined as the volume enclosed by all tissues in the callus zone,
and the callus bone volume (BV) was defined as the volume of the callus containing only
mineralized tissue. The percentage of BV/TV fraction was calculated as the ratio of bone
volume to total volume multiply by 100.

3.6 Immunofluorescence staining:
To visualize cilia on osteoblasts and test the proliferation of osteoblasts,
immunofluorescence staining was performed on histological slides from D21 post-fracture
using primary acetylated α-tubulin antibody (Sigma-Aldrich, St. Louis, MO, USA; 1:500)
and Ki67 antibody (Abcam, Cambridge, MA, USA; 1:300, ab16667), respectively. After
hydrating and washing the section with PBS as mentioned above, antigen retrieval was
performed. Slides were placed in a boiled 10mM sodium citrate buffer PH=6 and then
maintained at a sub-boiling temperature (95OC) for 25 minutes. Later, slides were cooled
on the bench for one hour. Following antigen retrieval, permeabilization was performed
with 0.05% Triton X-100, blocked in 5% normal goat serum (Vector laboratories S-100020) for one hour. Then the sections were incubated with primary antibodies (mentioned
above) overnight at 4 °C. Sections were then washed three times for 10 minutes each and
incubated with Alexa Fluor 594-conjugated anti-rabbit (1:1,000, A-11007, Invitrogen) or
Alexa Fluor 647-conjugated anti-mouse (1:1,000, A-21236, Invitrogen) secondary
antibodies for one hour at room temperature. After washing the sections, slides were
mounted with VectaShield containing 4,6-diamidino-2-phenylindole (DAPI) (Vector
Laboratories, Burlingame, CA, USA). Images were captured and processed with Leica
DMI6000 inverted epifluorescence microscope under ×40 lens. To quantify the percentage
of ciliated cells, twelve fields of callus were randomly selected from each specimen and
Z-stacked pictures were captured. The percentage of cilia-positive osteoblasts for each
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slide was obtained by calculating the number of ciliated bone lining cells divided by the
number of DAPI-positive cells around the bone particles. The same procedure was used
for Ki67 staining analysis. Exposure time was adjusted using the threshold of the highest
exposure time with no signal in the matched IgG control antibody (1:500, Thermo
Scientific 31903) for acetylated α-tubulin antibody and the matched control IgG antibody
(1:300, Thermo Scientific, 02-6102) for Ki67 antibody.

3.7 Mechanical testing:
To evaluate the mechanical properties of the fracture femur callus at the bone
remodeling stage, fracture femur calluses were harvested at D35. Fracture femur
specimens were isolated by removing the soft tissue thoroughly, evaluated by microCT.
Specimens were then stored in PBS at -20 °C freezer until mechanical analysis. Prior to
mechanical testing, samples were kept in PBS at room temperature for one hour and then
subjected to mechanical testing. The mechanical assays were performed at the
Biomechanics Core in Penn Center for Musculoskeletal Disorders (PCMD).
The 4-point bending assay was performed using an electromechanical testing
machine (Instron 5542, Instron Inc., Norwood, MA). The lower supports were 5.4 mm
apart, and the upper loading pin was in the center of the lower supports. The bending load
(F) was applied with two tips of a bracket. The distance (d) between each support and the
bracket tip was kept constant for all samples. The fracture femurs were loaded in the
longitudinal direction and the load was applied using a 50 N load cell (Instron Inc.,
Norwood, MA) until the callus failed. All of the failure happened in the middle of callus
(Figure 9). The load was recorded via the Instron system against sample deflection up to
a maximum force of 50 N at a crosshead displacement of 0.03 mm s−1. The slope (y/x)
of the linear region of the load-displacement curve was used to measure stiffness (N/mm).
Elastic modulus was calculated by the following formula: KL3/(48 Imin), where K = stiffness,
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L = span length, Imin = minimum value of bending moment of inertia. The Imin value which
corresponds to the orientation of the callus that provides the least resistance to bending
was calculated from microCT images.

Figure 9. The 4-point bending
assay was set up based on the
average of the femur length
and verification of failure was
confirmed in the middle of the
callus.

For torsion analysis, first, each end of fracture femur specimens was embedded in
poly-methylmethacrylate (PMMA) inside a custom-made potting apparatus to align the
samples with the diaphyseal axis (Figure 10). Care was taken to keep the samples
hydrated

with

PBS

during

preparation.

Samples

were

mounted

within

the

electromechanical testing machine (Instron 5542, Instron Inc., Norwood, MA) with a
custom-designed torsional testing motor, then load was applied using a 0.035 Nm
torsional load cell at a rate of 1o/s until the failure of samples (Figure 10). Maximum torque
to failure (Max. Torque) and modulus of rigidity were quantified from the resultant torsionangular displacement data. Modulus of rigidity was calculated by the following formula:
TL/ φJ, which T=maximum torque, L=guage length of specimen (mm), and φ=angular
displacement (deg) at maximum torque, and J= polar moment of inertia which represents
the resistance of the callus to torsion calculated from Micro-CT images.
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Figure 10. The torsional testing
set up. Fracture femur
specimen was embedded in
PMMA to ensure proper
alignment. Failure occurred in
the middle of the callus.

3.8 Quantitative RT-PCR and Western blot:
The fracture calluses from D21 post-fracture were cut from the femur right after
removing adjacent soft tissue. Fracture calluses were snap-frozen, pulverized and
homogenized in radioimmunoprecipitation assay (RIPA) buffer (Thermo Fisher Scientific,
Waltham, MA, USA) supplemented with protease inhibitors (Thermo Fisher Scientific,
Waltham, MA, USA). Lysates were centrifuged, and the protein concentration in the
supernatant of each sample was determined using a BCA protein assay (Pierce, Rochford,
IL). The protein samples (20 μg /lane) were subjected to electrophoresis on a 12% SDS–
PAGE gel and then transferred to a nitrocellulose membrane. After the membrane was
blocked for one hour using a 5% milk–Tris-buffered saline Tween-20, the membrane was
incubated with primary antibodies diluted in 5% BSA blocking solution overnight at 4OC.
Rabbit anti-IFT80 antibody (1:400) from Abnova (PAB15842) and rabbit anti-Foxo1
(1:500) antibody from Cell Signaling Technology (2880S) were used. Then, the membrane
was incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG
antibody dilutes in 5% milk blocking solution (1:10.000, A-11034, Novex, Carlsbad, CA) at
room temperature for one h. Visualization was performed with ChemiDoc Touch (Bio-Rad
Laboratories, Hercules, CA, USA) imaging system. Beta-actin diluted in 5% milk blocking
solution (1:2,000, A00191, Genscript) was used as a loading control. Protein band
intensities were measured using ImageJ software, normalized to beta-actin.
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For quantitative RT-PCR, total RNA from D14 fractured callus specimens was isolated
from snap-frozen and finely crushed callus in Trizol (Life Technologies, Inc., Grand Island,
NY, USA) following the manufacturer’s instructions. RNA concentration was quantified
NanoDrop™ 2000 (Thermo Fisher Scientific), and cDNA was prepared from 1 μg total
RNA using the PrimeScriptTM RT reagent kit (Takara Bio). Quantitative RT-PCR was
performed with SYBR Green PCR master Mix (Invitrogen) and mouse-specific primers
(Bio-Rad Laboratories, Hercules, CA, USA) on CFX96 real-time PCR machine (Bio-Rad
Laboratories, Hercules, CA, USA). Relative gene expression was calculated using the
delta-delta comparative threshold cycle algorithm (2–ΔΔCT) method and normalized to
GAPDH as an endogenous control. To calculate the fold change in the target gene, the
relative gene expression of each group was referenced to the control group (NG OsxcretTA).
Primer sequences are listed in Table 2.
Table 2. List of primers sequence for RT-qPCR.
Name
Forward primer sequence
IFT80

Reverse primer sequence

AAGGAACCAAAGCATCAAGAATTAG

AGATGTCATCAGGCAGCTTGAC

ACAACCACAGAACCACAAG

TCTCGGTGGCTGGTAGTGA

OSX

AGCGACCACTTGAGCAAACAT

GCGGCTGATTGGCTTCTTCT

ALP

ATCTTTGGTCTGGCTCCCATG

TTTCCCGTTCACCGTCCAC

OCN

GCAATAAGGTAGTGAACAGACTCC

GTTTGTAGGCGGTCTTCAAGC

Col-1

GCAACAGTCGCTTCACCTACA

CAATGTCCAAGGGAGCCACAT

Foxo1

GCTGCATCCATGGACAACAACA

CGAGGGCGAAATGTACTCCAGTT

ACTTTGTCAAGCTCATTTCC

TGCAGCGAACTTTATTGATG

Runx-2

GAPDH

3.9 In-vitro preparation of advanced glycation end products (AGEs):
To simulate diabetic conditions in-vitro, we prepared AGE-modified bovine serum
albumin (BSA) as described by Valcourt et. al [221]. Briefly, 50 mg/ml BSA with 0.6M Dribose in phosphate- buffered saline (PBS; pH 7.4) were incubated in 37°C, 5% CO2
humidified incubator, under sterile conditions and protected from light for one week. Then,
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the dialysis was performed against PBS for three days using SnakeSkinTM dialysis tubing
(ThermoFisher Scientific) to remove unincorporated ribose. The formation of AGEs was
confirmed by brown color development, pentosidine production based on characteristic
fluorescence, and western blot for RAGE induction in pre-osteoblasts (POBs) cultures.
To detect RAGE expression in a dose-dependent manner, POBs were isolated from
the calvarial bone of 3-5 days old of neonatal mice and treated with different doses of
AGEs (50, 100, 150 ug/ml) and 150 ug/ml BSA (control for AGEs) for three days. Then,
cells were lysed in the RIPA buffer containing protease inhibitors. Five ug of proteins were
subjected to 10% SDS-PAGE membrane and transferred onto nitrocellulose membranes.
Immunoblotting analysis was performed as mentioned in the “Quantitative RT-PCR and
Western blot” section using mouse anti-RAGE antibody from Santa Cruz Biotechnology
(1:2000, sc-365154) as a primary antibody and anti-mouse IgG antibody (1:1000, 115035-003) from Jackson ImmunoResearch as a secondary antibody. The band intensities
were measured using ImageJ software, normalized to beta-actin.
The cytotoxic effect of AGEs on POBs was examined with the Alamar blue assay (BioRad Laboratories, Hercules, CA, USA). POBs were seeded in 96-well plates at a density
of 3 × 103 cells/well for one day. Cells were then incubated with different doses of AGEs
(50, 150, 250 ug/ml) or control BSA (150 ug/ml) for 24 hours (h), 48 h and 72 h. Then, the
Alamar blue reagent was added to each well and gently mixed. After 4 hours of incubation
at 37°C, 5% CO2 humidified incubator, the absorbance at 570 nm was measured in
microplate reader with a reference wavelength at 600 nm. The cytotoxicity was calculated
based on the formula recommended by the company.
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3.10 Isolation of pre-osteoblasts and adenoviral-cre transduction:
Pre-osteoblasts (POBs) were isolated from IFT80f/f and Foxo1f/f mouse calvarial bone
(postnatal day 3-5) by serial digestion. Briefly, calvariae were isolated, washed with cold
PBS, and incubated in collagenase type II (2 mg/ml, EMD, Darmstadt, Germany), Trypsin
(0.25%, Corning, Manassas, VA) for 30 minutes. Calvarial bone was then minced and
subjected to collagenase type II (2 mg/ml) and trypsin again for ten minutes before being
plated in complete α-modified Eagle medium (Fisher Scientific) (α-MEM) supplemented
with 10% fetal bovine serum (Gibco), L-glutamine (2 mM/ml) (Life Technologies) and
penicillin/streptomycin (100 U/ml) (Life Technologies). POBs were infected with
Adenoviruses- Cre (Ad-CMV-Cre; Vector Biolabs, Malvern, PA, USA; #1405) or
Adenoviruses-Null (Ad-Null; Vector Biolabs, Malvern, PA, USA; #1300). Briefly, POBs
were seeded at about 80% confluency and treated with Ad-Cre or Ad-Null in serum-free
media for four hours and then 2% serum was added to the cells and incubated overnight.
The next day, the virus-containing media was completely removed and replaced by
complete α-MEM. After two days recovery, the cells were trypsinized and seeded for
experiments. Cells treated with Ad-Cre were labeled as IFT80d/d and Foxo1d/d, and cells
treated with Ad-Null were used as control and named as IFT80f/f and Foxo1f/f. Virus
transduction was performed on cells at passage two, and cells at passage three were
used for experiments.

3.11 Osteogenic differentiation in-vitro:
For osteogenic differentiation, POBs were seeded at a density of 1,000,000 cells/ml
and reached 100% confluency, and then treated with an osteogenic medium in α-MEM
(Gibco) containing 10% FBS, 10 mM β-glycerophosphate (Sigma, St Louis, MO),
50 μg/ml ascorbic acid (Sigma) and 10−8 M dexamethasone (Sigma) supplemented with
AGEs (150 ug/ml) and control BSA (150 ug/ml) for 21 days. To measure bone nodule
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formation, extracellular matrix calcium deposits were stained with Alizarin Red solution.
For quantification, stained cells were destained with 10% cetylpyridinium chloride in
10 mM sodium phosphate (pH 7.0), and the optical density was measured at the
wavelength of 562 nm.

3.12 In-vitro quantitative RT-PCR:
POBs were seeded at a density of 1,000,000 cells/ml to reach 100% confluency and
then induced with osteogenic media supplemented with AGEs (150 ug/ml) or BSA (150
ug/ml) for fivw days. Total RNA was isolated from the cells with Trizol Reagent (Life
Technologies, Inc., Grand Island, NY, USA) as mentioned in the “Quantitative RT-PCR
and Western blot” section for assessing IFT80, Foxo1 and osteoblast markers expression
levels. After calculating relative gene expression using 2–ΔΔCT method and normalizing to
GAPDH as endogenous control, the relative gene expression of each group was
referenced to the control group (BSA IFT80d/d or BSA Foxo1f/f) to calculate the fold change
in the target genes.

3.13 Immunofluorescence in-vitro:
POBs were seeded at the density of 8x105 cells/ml to reach 70% confluency. After
being pretreated with AGEs and control BSA for five days [121,126], the POBs were
incubated in serum-free media overnight with AGEs or BSA for cell ciliation. Then, cells
were washed with PBS and fixed with 4% paraformaldehyde for ten minutes. Fixed cells
were permeabilized with 0.05% Triton X-100 for 5 minutes and blocked in 5% normal goat
serum (Vector laboratories S-1000-20) for one hour followed by the incubation with
acetylated α-tubulin antibody (1:500, T6793, Sigma) overnight at 4 °C. After washing, cells
were incubated with Alexa Fluor 647-conjugated anti-mouse (1:1,000, A-21235,
Invitrogen) antibody as a secondary antibody for one hour at room temperature. Then
slides were mounted with VectaShield containing DAPI (Vector Laboratories, Burlingame,
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CA, USA). Images were captured by an inverted epifluorescence microscope under ×40
lens with the same exposure time for both the control (1:500, Thermo Scientific 31903)
and the experimental group. The number of ciliated cells and cilia length were randomly
measured in twenty-five fields per coverslip (three coverslips per group). The percentage
of ciliated cell number over total cell number and cilia length were analyzed using a free
hand tool in Leica microscope software.
For Foxo1 staining, POBs were plated in 24-well plates at 6 × 105 cells per well and
incubated with 150 μg/ml BSA or AGE for three days. After fixing and permeabilizing, cells
were incubated with primary anti-Foxo1 antibody (1:200, cell signaling technology 2880S)
or nonspecific IgG (1:200, Thermo Scientific, 02-6102) overnight at 4 °C. Then, cells were
incubated with the Alexa Fluor 594- Anti-Rabbit IgG secondary antibody (1:500, Jackson
ImmunoResearch, 111-585-144) for one hour at room temperature. Slides were mounted
using VectaShield containing DAPI (Vector Laboratories, Burlingame, CA, USA). Images
were captured at 20x magnification using the inverted epifluorescence microscope. The
percentage of Foxo1 nuclei-positive cells was calculated by the number of Foxo1 nucleipositive cells divided by the total number of cells.

3.14 Chromatin immunoprecipitation (ChIP):
The pre-osteoblastic cells lines MC3T3-E1 (ATCC) were incubated with 200 ug/ml
AGEs and 200 ug/ml BSA as a control for three days and starved overnight. Then,
Chromatin immunoprecipitation (ChIP) assays were carried out by the senior laboratory
member Dr. Gonsheng Yuan according to the manufacturer's protocol (Cell Signaling
Technologies, 9004S). Briefly, Formaldehyde (1% final concentration) was added directly
to culture medium for 10 min at room temperature to cross-link DNA and quenched with
glycine to a final concentration of 0.125 M for another 5 min. The cells were lysed and
sonicated on ice followed by immunoprecipitation overnight with 5 ug anti-Foxo1 antibody
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(cell signaling technology 2880S) or normal rabbit IgG (Cell Signaling Technology, 2729),
mixed with ChIP-Grade Protein G Agarose beads (cell signaling technology 9007).
Protein-DNA complexes were eluted from the beads, followed by a reverse cross-linked
step overnight at 65 °C and deproteinated with proteinase K at 56 °C for 30 min. After
reversal of protein-DNA cross-links, the DNA was purified using DNA purification spin (cell
signaling technology, 10010). RT-qPCR reaction for was performed with IFT80 promoter
primer

[IFT80F

(5′-TGGTCGCAGGACAGCCTTTG-3′)

and

IFT80R

(5′-

CAGTTCCAGAGAAATGTTAAATACCGC-3′)] which has the consensus of Foxo1 binding
site.

3.15 Gain of function assay:
The MC3T3-E1 cell lines were seeded on 6-well plates at 2 × 105 cells/well
(approximately 85-90% confluency). Cells were transfected with a constitutively active
Foxo1 expression plasmid, GFP-Foxo1 (Addgene), or pCMV control plasmid using
FuGENE HD Transfection Reagent (Promega Corporation). Cells were harvested at 48
hours after transfection, and total RNA was isolated from the cells as mentioned above in
the “In-vitro quantitative RT-PCR” section. After verifying the Foxo1 overexpression, IFT80
mRNA level was assessed by qRT-PCR.

3.16 Luciferase reporter assay:
POBs were isolated from Foxo1f/f mouse calvarial bone and infected with
Adenoviruses- Cre or Adenoviruses-Null control. Then, the cells were seeded in 96-well
plate at 5000 cells/well. At 60% confluency, cells were pretreated with 150 ug/ml AGEs
and 150 ug/ml BSA for three days. Cells were then transfected with pLightSwitch-IFT80
plasmid (S720959, SwitchGear Genomics) and pLightSwitch vector (S790005,
SwitchGear Genomics) as a control using FuGENE HD Transfection Reagent (Promega
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Corporation). Two days after transfection, cells were starved overnight and then lysed.
The IFT80 luciferase activity was detected using LightSwitch Luciferase Assay Kit
according to the manufacturer’s instruction.
We further investigated if Foxo1 overexpression affects IFT80 expression by
performing a luciferase reporter assay. The MC3T3-E1 cell lines were seeded on 96-well
plates at 5000 cells/well. At 85% confluency, cells were cotransfected with pLightSwitchIFT80 plasmid (SwitchGear Genomics) and pLightSwitch vector control (SwitchGear
Genomics), together with a constitutively active Foxo1 expression plasmid, GFP-Foxo1
(Addgene), or pCMV control plasmid using FuGENE HD Transfection Reagent (Promega
Corporation). Two days after transfection, cells were starved overnight and then lysed to
measure the IFT80 luciferase activity by LightSwitch Luciferase Assay Kit.

3.17 Sample size calculation:
The sample size for in-vivo experiments was calculated based on a power analysis
using SigmaStat Statistical Software. We used the BV/TV values from Micro-CT data [222]
to detect a statistical significance of difference. To reach a power of 80% (α = 0.05, a
difference of 50% in the BV/TV value, Sd of 30%, 2-sided t-test), a sample size of seven
mice per group was estimated for the D21 endpoint. For biomechanical testing, we
increased the power to account for the expected high variability of the results during
fracture healing. Based on published data [187] to reach a minimum power of 90% (α =
0.05, a mean difference of 60% in the modulus of rigidity value, Sd of 40%, 2-sided t-test),
ten mice per group were estimated for the D35 endpoint. All in-vitro experiments were
carried out in triplicate and repeated three times.
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3.18 Statistical analysis:
Statistical analysis was performed using Prism software (GraphPad version 8).
When only two groups were analyzed, statistical significance was determined using
Student’s t-test. For multiple groups analysis, two-way ANOVA was used, and when
significance difference was observed Tukey’s multiple-comparison post hoc test was
carried out to determine pairwise significance. All data are presented as the
mean ± standard deviation (Sd). P< 0.05 was considered to be statistically significant.
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Chapter 4
RESULTS
4.1 Gene deletion confirmation
We confirmed the mice genotyping by PCR analysis of DNA obtained from a toe
biopsy using Cre, IFT80 and Foxo1 primers. IFT80 with flanking loxP sites (469 bp) with
Cre recombinase (281 bp) was detected in the OSXcretTAIFT80f/f mice, whereas in the
control mice (OSXcretTA) the wild type band (247 bp) with Cre recombinase (281 bp) was
present (Figure 11. A). Foxo1 with flanking loxP sites (300 bp) with Cre recombinase (281
bp) was detected in the OSXcretTAFoxo1f/f mice (Figure 11. B). In OSXcretTAIFT80f/fFoxo1f/f
mice, both IFT80 and Foxo1 with flanking loxP sites (469 and 300 bp, respectively) with
Cre recombinase (281 bp) were found (Figure 11. C).

Figure 11. Genotyping results. (A) Genotyping of OSXcretTAIFT80f/f and control littermate mice. (B) Genotyping
of OSXcretTAFoxo1f/f mice. (C) Genotyping of OSXcretTAIFT80f/fFoxo1f/f mice.
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We also confirmed the deletion of IFT80 in OsxcretTAIFT80f/f, OsxcretTAFoxo1f/f and
OsxcretTAIFT80f/f Foxo1f/f in the fracture femur callus specimens via RT-qPCR on D14 postfracture (Figure 12).

Figure 12. Confirmation of the gene deletion in fracture femur calluses two weeks after withdrawing
doxycycline. (A) Real time RT-qPCR analysis of IFT80 expression of OSXcretTA (control) and OSXcretTAIFT80f/f
fracture callus. (B) Real time RT-qPCR analysis of Foxo1 expression of OSXcretTA (control) and OSXcretTAFoxo1f/f
fracture callus. (C) Real time RT-qPCR analysis of Foxo1 and IFT80 expression of OSXcretTA (control) and
OSXcretTAIFT80f/fFoxo1f/f fracture callus. In all the experiments n=3 mice/group. * P < 0.05,  P < 0.01.

4.2 AGEs production and dose optimization in in-vitro POB culture
AGEs were produced based on the published paper [221]. The formation of AGEs was
confirmed by the following criteria: brown color development, presence of pentosidine by
performing fluorescence analysis (Ex./Em. = 370/440 nm), and dose-dependent
expression of RAGE in POBs treated with different doses of AGEs (Figure 13).
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Figure 13. AGEs fabrication confirmation. (A) BSA was incubated D-ribose as described in the Material
and Methods section to produce AGEs. Glycated BSA (AGEs) develop brown color compared to BSA
(control). (B) Pentosidine concentrations were determined in AGE-modified BSA, unmodified BSA and PBS.
(C) Western blots showed dose-dependent increases in RAGE protein levels in POBs treated with different
concentration of AGEs compared to 150 µg/ml unmodified BSA for three days.

To investigate the best concentration of AGEs for POBs, IFT80f/f POBs were treated
with 50, 150 and 250 ug/ml of AGEs for 24, 47 and 72 h. The result from Alamar blue
assay showed that POBs treated with the high dose of AGEs (250 ug/ml) had reduced
viability; however, lower doses of AGEs (50 and 150 ug/ml) did not reduce viability (Figure
14. A). By assessing the cilia formation in response to the different doses of AGEs, we
found that the low dose of AGEs (50 ug/ml) did not affect cilia formation in POBs whereas
the higher dose of AGEs (150 ug/ml and 250 ug/ml) significantly reduced cilia formation
in POBs (Figure 14. B & C, P<0.001). Since 150 ug/ml concentration of AGEs was not
cytotoxic to the POBs and adversely affected cilia formation, we chose 150 ug/ml
concentration of AGEs for in-vitro studies.
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Figure 14. The effect of different doses of AGEs on the viability and cilia formation of POBs. (A) POBs were
incubated with AGEs at various concentration (50, 150 and 250 ug/ml) for 24, 48, or 72 h and cell viability
was analyzed via Alamar blue assay. Data from three independent experiments. (B, C) Immunofluorescence
of POBs incubated with various concentration of AGEs using anti-acetylated α-tubulin (red) antibody to
visualize cilia (40x) and quantitation of cells with cilia. To count the percentage of ciliated POBs, twenty-five
fields per coverslip were randomly selected and measured. Data from one representative experiment of
three independent experiments are shown. * P < 0.05; # P < 0.001.

Then we checked the cell viability, differentiation and ciliogenesis of POBs in different
conditions as follow: 150 ug/ml AGEs vs 150 ug/ml BSA (as a control for AGEs), HG (25
mM) vs Mannitol (25 mM, as an osmolarity control to HG) and NC (negative control, no
chemical addition). Cell viability was not affected in POBs treated with different conditions
(Figure 15. A). However, AGEs treatment significantly reduced cilia formation and
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impaired osteoblast differentiation as demonstrated by reduced Alizarin Red
accumulation. HG condition did not affect the POBs’ differentiation and ciliogenesis
(Figure 15. B &C). Based on the optimization results, we chose 150 ug/ml AGEs to mimic
the diabetic condition in-vitro.

Figure 15. The effect of different conditions on the viability, differentiation, and cilia formation of POBs. (A)
POBs were incubated with 150 µg/ml AGEs, 150 µg/ml unmodified BSA (as a control for AGEs), 25mM HG,
25 mM mannitol (as an osmotic control for HG) for 24, 48, 72 and 120 h and cell viability were analyzed via
Alamar blue assay. (B) Alizarin Red staining and quantitative analysis of POBs in osteogenic media treated
with 150 µg/ml AGEs, 150 µg/ml BSA, 25mM HG, 25 mM mannitol for 21 days. (C) Immunofluorescence of
POBs incubated with 150 µg/ml AGEs, 150 µg/ml BSA, 25mM HG, 25 mM mannitol for 5 days using antiacetylated α-tubulin (red) antibody to visualize cilia (40x) and quantitation of cells with cilia. Data from three
independent experiments. * P < 0.05,  P < 0.01, # P < 0.001.
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4.3 To determine the effect of IFT80 deletion in osteoblast lineage
and diabetes on bone formation and bone remodeling in fracture
femur callus.
IFT80 deletion in osteoblast lineage is comparable to diabetes in
inhibiting new bone formation in the fracture callus
Axial and 3D reconstruction of microCT images from fracture calluses on D21
demonstrated less bone mass with low bone density in the experimental groups (NG
OsxcretTAIFT80f/f, Dia OsxcretTA and Dia OsxcretTAIFT80f/f) compared to normoglycemic
controls (NG OsxcretTA) (Figure 16. A). The ratio of bone volume/total volume (BV/TV) in
diabetic control (Dia OsxcretTA) and normoglycemic experimental (NG OsxcretTAsIFT80f/f)
mice was decreased by 60% and 64%, respectively, compared to NG OsxcretTA mice
(Figure 16. B). Interestingly, IFT80 deletion in diabetic mice did not have a further impact
on fracture healing compared to the effect of diabetes alone (P>0.05). This finding showed
that IFT0 deletion in osteoblasts and diabetes dramatically decreased bone formation.
Similarly, connectivity density value (Conn-Dens) was significantly reduced in Dia OsxcretTA
mice as well as NG OsxcretTAIFT80f/f and Dia OsxcretTAIFT80f/f mice compared to NG control
mice (P < 0.05) with no statistical difference between the three experimental groups (P >
0.05) (Figure 16. B). This result demonstrated that IFT80 deletion in osteoblasts and
diabetes limited the trabecular bone density in the fracture callus.
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Figure 16. IFT80 deletion in osteoblast lineage and diabetes impaired the callus bone architecture. (A)
Representative images of 3D reconstruction and sections of microCT scans of the fracture site at D21
post-fracture of NG OSXcretTA (control), OSXcretTAIFT80f/f, Dia OSXcretTA and Dia OSXcretTAIFT80f/f mice
(experimental groups). (B) Quantitative measurements of the percentage of bone volume to total bone
volume (BV/TV) and connectivity density (Conn-Dens) at fracture site on D21 (n=8-9 mice per group).
 P < 0.01, # P < 0.001. NG: normoglycemic, Dia: Diabetic. Scale bar: 1mm.

Specimens from D21 post-fracture were further analyzed histologically to assess the
effect of IFT80 deletion and diabetes on bone formation. Consistent with micro-CT results,
BV/TV in Dia OsxcretTA mice and Dia OsxcretTAIFT80f/f mice significantly was reduced by
44% and 49% compared to that in NG OsxcretTA group (P<0.05). Diabetic mice had a
reduction in bone formation that was comparable to the decrease in NG OsxcretTAIFT80f/f
(P>0.05) and the deletion of IFT80 in diabetic mice had no further effect (P>0.05) (Figure
17. A & B). To further investigate the influence of diabetes and IFT80 deletion on
osteogenic differentiation in the fracture callus, mRNA levels of ALP and OCN were
measured in callus specimens. Expression of ALP and OCN were downregulated to a

48

similar extent in the three experimental groups (NG OsxcretTAIFT80f/f, Dia OsxcretTA and Dia
OsxcretTAIFT80f/f) (P>0.05) (Figure 17. C).

Figure 17. Histological analysis of fracture callus. (A, B) Safranin O staining of longitudinal sections of
the fracture site from NG OSXcretTA (control), OSXcretTAIFT80f/f, Dia OSXcretTA and Dia OSXcretTAIFT80f/f mice
(experimental groups) at D21 post-fracture and quantification of bone area normalized to callus area
(BV/TV) (n= 6 mice per group). (C) Real time RT-qPCR analysis of markers of osteoblast, ALP and OCN,
extracted from the fracture calluses of four groups (NG OSXcretTA, NG OSXcretTAIFT80f/f, Dia OSXcretTA and
Dia OSXcretTAIFT80f/f) at D14 post-fracture (n=3 mice per group). * P < 0.05,  P < 0.01, # P < 0.001. NG:
normoglycemic, Dia: Diabetic. Scale bar: 1mm.

Ablation of IFT80 in osteoblast lineage showed the same phenotype
as diabetes in reducing bone mechanical strength in the fracture
callus
To further test bone regeneration in fracture at later stage during bone remodeling
phase, the fractured femurs on D35 post-fracture were harvested for Micro-CT analysis
and then performing mechanical analysis. Quantitative microCT analysis showed that NG
OsxcretTAIFT80f/f caused a 58% reduction in BV/TV compared to the NG. control mice
(P<0.001). Dia OsxcretTA and Dia OsxcretTAIFT80f/f mice had 60% and 64% reduction in
BV/TV compared to the NG OsxcretTA mice, respectively (P<0.001) and there was no
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significant difference between any two of these three groups (the NG OsxcretTAIFT80f/f, Dia
OsxcretTA and Dia OsxcretTAIFT80f/f groups) (P >0.05) (Figure 18. A & B). Also, connectivity
density decreased significantly in these three experimental groups (OsxcretTAIFT80f/f,
diabetic and the combination) in comparison to the control mice but these three
experimental groups did not demonstrate a statistical difference between them (P>0.05)
(Figure 18. B).
After microCT, we performed a four-point bending analysis to test the mechanical
properties of the femur. The callus stiffness in the NG OsxcretTAIFT80f/f, diabetes and Dia
OsxcretTAIFT80f/f groups were significantly decreased by 33%, 50% and 49% compared to
that in the control mice, respectively. Modulus was dramatically decreased by IFT80
deletion (56%, P<0.01) and diabetes (66% in both diabetic and combination groups)
compared with that of NG control mice (P<0.001) (Figure 18. C).
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Figure 18. IFT80 deletion in osteoblast lineage and diabetes impaired bone quality and mechanical
strength of fracture callus. (A, B) MicroCT scan, 3D reconstruction and quantitative analysis of the
fracture site of NG OSXcretTA (control), NG OSXcretTAIFT80f/f, Dia OSXcretTA and Dia OSXcretTAIFT80f/f mice
(experimental groups) at D35 post-fracture (n= 8 mice per group). (C) Modulus and stiffness of the
femur at D35 post-fracture from NG OSXcretTA (control), NG OSXcretTAIFT80f/f, Dia OSXcretTA and Dia
OSXcretTAIFT80f/f mice (n= 7 per mice per group). * P < 0.05,  P < 0.01, # P < 0.001. NG: normoglycemic,
Dia: Diabetic. Scale bar: 1mm.
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4.4 To determine the impact of ablation of IFT80 in osteoblast
lineage and diabetes on ciliogenesis and proliferation of
osteoblasts
Ablation of IFT80 in osteoblast lineage and diabetes impaired cilia
formation and proliferation of bone lining cells
To assess the impact of diabetes and IFT80 deletion on cilia formation in-vivo,
immunofluorescence staining assays were performed with acetylated α-tubulin primary
antibody. Primary cilia were detected in 51% of bone lining cells in the D21 normoglycemic
control group, while only 14% ciliated bone lining cells were detected in the NG
OsxcretTAIFT80f/f (P<0.001), 9% in Dia OsxcretTA and 6% in the Dia OsxcretTAIFT80f/f groups
(P<0.001) (Figure 19. A & B). There was no significant difference among the three
experimental groups (P>0.05). The IFT80 protein level in the fracture callus was also
evaluated by Western blot analysis. The results showed that the IFT80 protein levels were
reduced by 60% in NG OsxcretTAIFT80f/f group, and 75% and 82% in Dia OsxcretTA and Dia
OsxcretTAIFT80f/f mice, respectively (P<0.001) compared with IFT80 protein level in the
control group (P<0.001) (Figure 19. C & D).
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Figure 19. IFT80 deletion in osteoblast lineage and diabetes condition decreased the cilia formation of
osteoblasts in fracture callus. (A, B) Z-stacked 3D deconvolution immunofluorescent images with antibody
specific for acetylated α-tubulin (red) to visualize cilia and quantitative analysis of the ciliated bone lining
cells percentage in the fracture calluses of NG OSXcretTA, NG OSXcretTAIFT80f/f, Dia OSXcretTA and Dia
OSXcretTAIFT80f/f mice at D21 post-fracture (n= 6 mice per group). Nuclei were identified by DAPI
counterstained. The white dotted line indicated the bone lining cells and the black dotted bone indicated the
surface of newly formed bone in fracture callus. Magnification: 40x. Scale bar: 10 µm. (C, D) Western blot
for IFT80 protein levels in fracture callus of the four groups mice at D21 post-fracture. IFT80 protein level
was normalized to beta-actin (n= 3 mice per group). * P < 0.05, # P < 0.001. NG: normoglycemic, Dia:
Diabetic. Scale bar: 10 µm.

To get further insight into the defective fracture healing in NG OsxcretTAIFT80f/f and Dia
OsxcretTA mice, osteoblast proliferation was measured by immunofluorescence staining
using Ki67 antibody in the fracture callus of D21 post-fracture. In the normal control group
49% of the bone lining cells were Ki67+ while the number was decreased to 30%, 32%
and 27% in NG OsxcretTAIFT80f/f, Dia OsxcretTA and Dia OsxcretTAIFT80f/f groups, respectively
(P<0.01) (Figure 20. A & B).
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Figure 20. IFT80 deletion in osteoblast lineage and diabetes condition reduced osteoblasts proliferation in
fracture callus. (A, B) Immunofluorescent images and analysis of Ki67-positive bone lining cells with
representative bright field images in sections from fracture calluses of NG OSX cretTA (control), NG
OSXcretTAIFT80f/f, Dia OSXcretTA and Dia OSXcretTAIFT80f/f mice (experimental groups) at D21 post-fracture (n= 6
mice per group). Nuclei were stained with DAPI. The white dotted line marked the bone lining cells and the
black dotted bone indicated the surface of newly formed bone in fracture calluses. Magnification: 40x.  P <
0.01. NG: normoglycemic, Dia: Diabetic. Scale bar: 10 µm.

No signal was detected in callus sections stained with matched control antibodies as
negative controls for acetylated α-tubulin and Ki67 antibodies (Figure 21).

Figure 21. Immunofluorescence with matched control IgG
for acetylated α-tubulin (A) and Ki67 (B). Sections were
from fracture calluses of control mice at D21 post-fracture.
No signal was detected in three slides stained with matched
control antibody. Nuclei were stained with DAPI. The white
dotted line marked the bone lining cells and the black
dotted bone indicated the surface of newly formed bone.
Magnification: 40x. Scale bar: 10 µm.
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IFT80 deletion and AGEs impaired osteoblast ciliogenesis and
differentiation in-vitro
To investigate mechanistically how diabetes and IFT80 deletion may affect
osteoblasts, POBs were isolated from IFT80f/f mice, infected with either Ad-Cre (IFT80d/d
POBs) or Ad-null (IFT80f/f POBs) viruses and incubated with either 150 ug/ml AGEs or
150 ug/ml BSA (control). IFT80 deletion or AGEs treatment substantially reduced the
formation of a mineralized matrix as demonstrated by reduced Alizarin Red accumulation
(Figure 22. A) and inhibited osteoblast differentiation as shown by reduced ALP,
OSX and Col-1 expression (Figure 22. B). Consistent with in-vivo findings, IFT80 deletion
combined with incubation with AGEs had no further effect on osteoblast differentiation
compared to cells incubated with AGEs alone (AGEs IFT80f/f).

Figure 22. IFT80 deletion and AGEs reduced osteoblast differentiation. (A) Alizarin Red staining and
quantitative analysis of IFT80f/f and IFT80d/d POBs treated with 150 µg/ml unmodified control BSA and 150
µg/ml AGEs at 21 days after incubation in osteogenic media. (B) Real time RT-qPCR analysis of osteogenesis
markers (ALP, OSX and Col-1) in POB cultures from IFT80f/f and IFT80d/d mice in osteogenic media with 150
µg/ml unmodified control BSA or 150 µg/ml AGEs for 5 days. Data from three independent experiments.  P
< 0.01, # P < 0.001.
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To determine whether AGEs reduced osteoblast cilia formation, immunoﬂuorescence
staining assay was carried out for analyzing cilia number and length in POBs. About 78%
of the POBs had cilia in the control group, unmodified BSA, while cilia numbers were
significantly reduced in the groups of IFT80 deletion (33%), AGEs (38%) and IFT80
deletion plus AGE incubation (30%) (P < 0.05). Moreover, cilia length in the BSA control
group was 2.4 um, which was significantly reduced by either IFT80 deletion, exposure to
AGEs or IFT80 deletion cells plus AGEs (0.93, 1.1 and 0.88 um, respectively) (P < 0.001)
(Figure 23. A & B). No signal was detected in POBs stained with the match control
antibody. Interestingly, POBs incubated with AGEs demonstrated a dramatic reduction in
ciliary IFT80 expression comparable the control group (Figure 23. C).

Figure 23. IFT80 deletion and AGEs impaired osteoblast differentiation and ciliogenesis in-vitro. (A, B)
Immunofluorescence with antibody specific for acetylated α-tubulin (red) to visualize cilia and matched
control antibody (negative control) in IFT80f/f and IFT80d/d POBs treated with150 µg/ml unmodified BSA or
150 µg/ml AGEs for 5 days. Quantitative analysis of the ciliated cells percentage and cilia length. (C) Real
time RT-qPCR analysis for IFT80 expression level in IFT80f/f and IFT80d/d POBs treated with 150 µg/ml
unmodified BSA or 150 µg/ml AGEs for 5 days. Data from three independent experiments. To count the
percentage of ciliated POBs, twenty-five fields per coverslip were randomly selected and measured. Data
from one representative experiment of three independent experiments are shown. Magnification: 40x. Scale
bar: 10 um. * P < 0.05; # P < 0.001.
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4.5 To evaluate the effect of Foxo1 deletion in osteoblast lineage on
bone formation and bone remodeling during diabetic fracture
healing
Osteoblast-specific Foxo1 deletion rescued the diabetes-reduced
bone regeneration
To evaluate the effect of Foxo1 deletion in osteoblast lineage on bone formation during
normoglycemic and diabetic fracture healing, microCT analysis was performed on fracture
calluses from NG OsxcretTA (control), NG OsxcretTAFoxo1f/f, Dia OsxcretTA (diabetic control)
and Dia OsxcretTAFoxo1f/f on D21 post-fracture. Axial and 3D reconstruction images of
microCT showed significantly less bone volume with porous woven bone in the NG
OsxcretTAFoxo1f/f and Dia OsxcretTA compared to the normoglycemic control mice (NG
OsxcretTA), while Foxo1 ablation in osteoblast of diabetic mice prevented the bone loss in
fracture callus (Figure 24. A). The BV/TV value in NG OsxcretTAsFoxo1f/f and diabetic (Dia
OsxcretTA) mice was reduced by 37% (P<0.05) and 58% (P<0.001), respectively, compared
to NG OsxcretTA mice (Figure 24. B). However, Foxo1 deletion in diabetic mice reversed
the negative impact of diabetes on fracture healing, showing no significant difference
compared to the control mice (NG OsxcretTA) (P>0.05). Consistently, ablation of Foxo1 in
osteoblast of normoglycemic mice (NG OsxcretTAFoxo1f/f) and diabetes (Dia OsxcretTA)
dramatically reduced the Conn-Dens compared to the control mice (NG OsxcretTA) (P<0.05
and P<0.001, respectively), but the Conn-Dens value was significantly restored in diabetic
mice with Foxo1 deletion (P> 0.05) (Figure 24.B).
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Figure 24. Osteoblast-specific deletion of Foxo1 decreased the bone formation in normoglycemic calluses
but restored the bone formation in diabetic calluses. (A) MicroCT scan, 3D reconstruction of NG OSXcretTA
(control), NG OSXcretTAFoxo1f/f, Dia OSXcretTA and Dia OSXcretTAFoxo1f/f mice at D21 post-fracture (B)
Quantitative analysis of the percentage of bone volume to total bone volume (BV/TV) and connectivity
density (Conn-Dens) of the fracture sites at D21 post-fracture (n=7-8 mice per group). * P < 0.05,  P <
0.01, # P < 0.001. NG: normoglycemic, Dia: Diabetic. Scale bar: 1mm.

Histological analysis also showed that the bone volume in the diabetic (Dia OsxcretTA)
and NG OsxcretTAFoxo1f/f mice reduced by 42% (P < 0.001) and 27% (P<0.01) compared
to normoglycemic control mice, respectively. However, lineage-specific deletion of Foxo1
in osteoblast restored the callus bone volume in the diabetic group to a level similar to that
of the normoglycemic group (P>0.05) (Figure 25. A & B). The ALP and OSX mRNA levels
were also tested in the fracture callus specimens on D14 post-fracture. Deletion of Foxo1
in osteoblasts (NG OsxcretTAFoxo1f//f) and diabetes (Dia OsxcretTA) markedly decreased the
ALP and OSX mRNA levels (P<0.001). In contrast, when Foxo1 was ablated in osteoblast
of diabetic mice (Dia OsxcretTAFoxo1f//f), the adverse effect of diabetes on ALP and OSX
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mRNA was largely reversed to the level that approximate the control mice (P> 0.05)
(Figure 25. C).

Figure 25. Foxo1 deletion in osteoblasts reduced bone volume in normoglycemic callus but reversed the
diabetic-reduced callus bone formation. (A) Safranin O staining of longitudinal sections of the fracture site
from of four groups (NG OSXcretTA (control), OSXcretTAFoxo1f/f, Dia OSXcretTA and Dia OSXcretTAFoxo1f/f) at D21
post-fracture. (B) Quantification measurements of bone area normalized to callus area (BV/TV) (n= 6 mice
per group). (C) Real time RT-qPCR analysis of ALP and OSX from the fracture calluses of four groups at D14
post-fracture (n=3 mice per group). * P < 0.05,  P < 0.01, # P < 0.001. NG: normoglycemic, Dia: Diabetic.
Scale bar: 1mm.

Ablation of Foxo1 in osteoblast lineage restored diabetes-impaired
callus mechanical strength
The effects of osteoblast-specific deletion of Foxo1 and diabetes on mechanical
properties of fracture femur calluses were measured on fracture calluses at D35 postfracture using a torsion test. The modulus of rigidity was reduced by 65% and 63 % in NG
OsxcretTAFoxo1f//f and Dia OsxcretTA compared to that in the control mice, respectively
(P<0.001). The maximum torques also dramatically decreased by 27% in both diabetic
mice and mice with osteoblast-specific deletion of Foxo1 compared to the control mice
(P<0.05). Interestingly, the diminished of mechanical strength caused by diabetes was
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reversed by deletion of Foxo1 in osteoblast. The modulus of rigidity and maximum torque
were restored to 87% and 100%, respectively in Dia OsxcretTAFoxo1f//f mice compared to
the control group, respectively (Fig, P>0.05) (Figure 26).

Figure 26. Mechanical properties changes in fracture femur calluses at D35 post-fracture. Torsion testing
was performed for fractured calluses of NG OSXcretTA (control), OSXcretTAFoxo1f/f, Dia OSXcretTA and Dia
OSXcretTAFoxo1f/f and Max. Torque and modulus rigidity were measured (n=9-11). * P < 0.05,  P < 0.01, # P
< 0.001. NG: normoglycemic, Dia: Diabetic.

4.6 To determine the effect of Foxo1 deletion in osteoblast lineage
on ciliogenesis and proliferation of osteoblasts
Osteoblast-specific Foxo1 deletion rescued the proliferation and
ciliogenesis of callus bone lining cells in diabetic mice
We first confirmed the Foxo1 deletion in callus of OsxcretTAFoxo1f/f mice using Western
blot analysis. There was 70% and 60% reduction in Foxo1 protein levels of NG
OsxcretTAFoxo1f/f and Dia OsxcretTAFoxo1f/f compared to that in control mice (P<0.05). In
diabetic mice, the Foxo1 protein level was substantially increased by 2-fold (P<0.01),
resulting in 69% reduction in IFT80 protein level of Dia OsxcretTA callus (P<0.001). Although
osteoblast-specific deletion of Foxo1 in normoglycemic mice did not affect IFT80
expression level, it surprisingly reversed the adverse impact of diabetes on IFT80
expression level to 78% of the IFT80 expression level in the control group (P>0.05) (Figure
27).
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Figure 27. Western blot analysis for Foxo1 and IFT80 protein levels in fracture callus. (A) Western blot
analysis of the fracture calluses of NG OSXcretTA (control), OSXcretTAFoxo1f/f, Dia OSXcretTA and Dia
OSXcretTAFoxo1f/f at D21 post-fracture. (B) Quantification of protein levels of Foxo1 and IFT80 were obtained
by imageJ and were normalized to beta-actin. The intensity of the bands was averaged from 3 different mice
per group. * P < 0.05,  P < 0.01, # P < 0.001. NG: normoglycemic, Dia: Diabetic.

To further evaluate the rescue effect of Foxo1 deletion on diabetes-reduced
ciliogenesis, immunofluorescence staining with acetylated α-tubulin primary antibody was
undertaken to assess cilia formation fracture in callus specimens of D21 post-fracture.
Primary cilia were present in 45% of bone lining cells in the control mice. Only 13% ciliated
bone lining cells were found in the Dia OsxcretTA (P<0.001) (Error! Reference source not f
ound..A & B), while deletion of Foxo1 in osteoblast of diabetic mice largely reversed the
cilia formation to 42% (Error! Reference source not found.. A & B). Osteoblast-specific d
eletion of Foxo1 in normoglycemic mice did not affect ciliogenesis of bone lining cells (40%
of bone lining cell showed cilia).
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Figure 28. Cilia formation reduced by diabetes was restored by Foxo1 deletion in callus
osteoblasts. (A) Z-stacked 3D deconvolution immunofluorescent images with acetylated α-tubulin
(red) to visualize cilia. (B) The percentage of ciliated bone lining cells in the fracture calluses of NG
OSXcretTA (control), OSXcretTAFoxo1f/f, Dia OSXcretTA and Dia OSXcretTAFoxo1f/f mice at D21 post-fracture
(n= 6 mice per group). Nuclei were identified by DAPI counterstained. The white dotted line indicated
the bone lining cells and the black dotted bone indicated the surface of newly formed bone in fracture
callus. Magnification: 40x. Scale bar: 10 µm.  P < 0.01, # P < 0.001.

Moreover, we evaluated the proliferation of bone lining cells by immunofluorescence
staining using Ki67 antibody in the fracture callus of D21 post-fracture. While 48% of bone
lining cells in NG OsxcretTA were Ki67+, this number was decreased to 31% and 26% in
NG OsxcretTAIFT80f/f (P<0.01) and Dia OsxcretTA (P<0.001) mice, respectively. Lineagespecific deletion of Foxo1 in osteoblasts restored the percentage of Ki67+ bone lining cells
in the diabetic group to 45%, which was not statistically different from the control group
(P>0.05) (Figure 29.A & B).

62

Figure 29. Deletion of Foxo1 in diabetic mice reversed the osteoblasts proliferation inhibited by diabetes.
(A) Immunofluorescent images with Ki67+ antibody and representative bright field images in fracture
calluses of NG OSXcretTA (control), OSXcretTAFoxo1f/f, Dia OSXcretTA and Dia OSXcretTAFoxo1f/f mice at D21 postfracture (n= 6 mice per group). Nuclei were counterstained with DAPI. The white dotted line marked the
bone lining cells and the black dotted bone indicated the surface of newly formed bone in fracture calluses.
(B) The percentage of Ki67+ bone lining cells in fracture calluses of the four groups. Magnification: 40x.
Scale bar: 10 µm. * P < 0.05,  P < 0.01, # P < 0.001.

No signal was detected in callus sections stained with matched control antibodies
(negative control) for acetylated α-tubulin and Ki67 antibodies (Figure 30).

Figure 30. Immunofluorescence with matched control
IgG for acetylated α-tubulin (A) and Ki67 (B) in sections
from D21 post-fracture of control mice. No signal was
detected in three slides stained with matched control
antibody. Nuclei were stained with DAPI. The white
dotted line showed the bone lining cells and the black
dotted bone indicated the surface of newly formed
bone in fracture callus. Magnification: 40x. Scale bar:
10 µm.
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Foxo1 deletion restored the AGEs-induced impaired ciliogenesis and
differentiation of osteoblasts in-vitro
To further investigate the mechanism by which Foxo1 deletion regulates osteoblasts,
POBs were isolated from Foxo1f/f mice, transfected with either Ad-Cre virus (Foxo1d/d
POBs) to delete Foxo1 in-vitro or Ad-null virus (Foxo1f/f POBs) as a control. Then, POBs
were incubated with 150 ug/ml AGEs or 150 ug/ml BSA (control). Foxo1 deletion or AGEs
markedly reduced Alizarin Red nodule formation and inhibited the expression levels of
osteoblast marker genes, including ALP, OSX and Col-1 (Figure 31. A, B). However,
deletion of Foxo1 restored the osteoblast differentiation and osteoblast markers
expression in POBs exposed to AGEs to the levels that were comparable to the control
group (BSA Foxo1f/f, P>0.05) (Figure 31. B).

Figure 31. Foxo1 deletion restored osteoblast differentiation in osteoblasts exposed to AGEs. (A) Alizarin
Red staining and quantitative analysis of Foxo1f/f and Foxo1d/d POBs treated with 150 µg/ml unmodified
control BSA and 150 µg/ml AGEs at 21 days after incubation in osteogenic media. (B) Real time RT-qPCR
analysis of osteoblast markers (ALP, OSX and Col-1) in Foxo1f/f and Foxo1d/d POB cultures in osteogenic
media with 150 µg/ml unmodified control BSA and 150 µg/ml AGEs for 5 days. Data from three
independent experiments. * P < 0.05,  P < 0.01, # P < 0.001.
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Consistent with in-vivo results, Foxo1 deletion did not affect osteoblast cilia formation
and cilia length; however, AGEs substantially reduced cilia formation and cilia length.
Primary cilia were identified in 73% of POBs in the control group and the average length
of cilia was 2.5 um. The cilia numbers and cilia length were reduced to 31% and 1.1 um
in POBs exposed to AGEs (P<0.001) (Figure 32. A & B). Interestingly, deletion of Foxo1
revered the cilia formation and length of POBs exposed to AGEs to the levels of those in
the control groups (67% and 2.2um, respectively) (P<0.001, Fig. 20 A & B). Moreover,
deletion of Foxo1 in POBs treated with AGEs restored the IFT80 mRNA expression level
to the normal level (P>0.05) (Figure 32. C).

Figure 32. Foxo1 ablation reversed the AGEs-reduced cilia formation in osteoblasts. (A, B)
Immunofluorescence with acetylated α-tubulin (red) to visualize cilia in Foxo1f/f and Foxo1d/d POBs exposed
to 150 µg/ml unmodified BSA or 150 µg/ml AGEs for 5 days and quantitative analysis of the percent ciliated
cells and cilia length. (C) Real time RT-qPCR analysis for IFT80 expression level in Foxo1f/f and Foxo1d/d POBs
treated with 150 µg/ml unmodified BSA or 150 µg/ml AGEs for 5 days. Magnification: 40x. Data from three
independent experiments. To count the percentage of ciliated POBs, twenty-five fields per coverslip were
randomly selected and measured. Data from one representative experiment of three independent
experiments are shown.  P < 0.01, # P < 0.001.

65

4.7 To investigate if Foxo1 transcriptional factor regulates IFT80
gene expression
AGEs enhanced Foxo1 interaction with IFT80 promoter
We first checked if AGEs exposure increases Foxo1 expression level and nuclear
transportation of Foxo1 transcriptional activity in POBs. AGEs incubation dramatically
increased Foxo1 transcriptional expression level by 3.5-fold compared to the control group
(Figure 33. A, P<0.01). In addition, IF staining using Foxo1 Ab showed that AGEs
treatment of POBs substantially promoted Foxo1 nuclear transportation by 4-fold (Figure
33. B & C and P<0.001). No signal was detected in cells stained with matched control
antibodies (Figure 33. C).

Figure 33. AGEs enhanced Foxo1 expression level and nuclear translocation. (A) Real time RT-qPCR analysis
for Foxo1 expression level in Foxo1f/f POBs treated with 150 µg/ml unmodified BSA or 150 µg/ml AGEs for
five days. (B, C) Immunofluorescence with Foxo1 antibody (green) and matched control IgG in Foxo1f/f treated
with 150 µg/ml unmodified BSA or 150 µg/ml AGEs for three days and quantitative analysis of the percentage
of Foxo1 nuclear localization. Magnification: 20x. To count the percentage of Foxo1 nuclear translocation,
ten fields per coverslip were randomly selected and measured. Data from one representative experiment of
three independent experiments are shown.  P < 0.01, # P < 0.001.
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To verify whether there is any possible association between Foxo1 transcription factor
and the IFT80 promoter, ChIP assays were performed following the manufacturer’s
instructions using an anti-Foxo1 antibody or control polyclonal nonspecific IgG. ChIP
results showed that Foxo1 interacted with the IFT80 promoter. AGEs incubation
stimulated 3.5-fold enrichment of Foxo1 association with IFT80 promoter compared with
cells incubated with BSA (P <0.001). Incubation with BSA (control) did not have a
significant effect on IFT80 promoter interaction, indicating that the increase in IFT80
interaction was due to the effect of diabetic conditions in-vitro (Figure 34).

Figure 34. Foxo1 interacted with IFT80 promoter in diabetic condition. MC3T3-E1 cell lines were treated with
200 ug/ml of unmodified BSA or 200 ug/ml AGEs for three days and ChIP assay was performed using antiFoxo1 antibody and matched control IgG antibody followed by real-time RT-qPCR. Data from three
independent experiments. # P < 0.01.

AGEs induced Foxo1 overactivation inhibited IFT80 gene expression
Luciferase reporter assay was undertaken to assess the possible regulatory effect of
IFT80 promoter by Foxo1 overexpression. MC3T3-E1 cell lines were cotransfected with
an IFT80 luciferase reporter (SwitchGear Genomics) or pLightSwich control plasmid
(SwitchGear Genomics) and Foxo1 overexpression (OE) (Addgene) plasmid or pCMV
plasmid (control) (Promega Corporation). Foxo1 overexpression dramatically reduced the
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IFT80 luciferase activity by almost 50% compared to the control cells (cells cotransfected
with IFT80 luciferase and pCMV plasmids) (P<0.01) (Figure 35. A).
Real time PCR results further showed that overexpression of Foxo1 resulted in 2.2fold downregulation of IFT80 genes expression level (P<0.01) (P<0.01) (Figure 35. B). We
further checked if deletion of Foxo1 can revere the IFT80 luciferase activity inhibited by
AGEs-induced Foxo1 overactivation. While AGEs reduced the IFT80 luciferase activity by
almost 56% compared to the control group (BSA Foxo1f/f), deletion of Foxo1 rescued the
IFT80 luciferase activity to 89% under AGEs stimulation compared to that in the control
group without Foxo1 deletion (P<0.001) (Figure 35. C).

Figure 35. AGEs upregulated Foxo1 activation leading to IFT80 gene expression inhibition. (A) IFT80
luciferase reporter assay of MC3T3-E1 cell lines cotransfection with control (pCMV) or FOXO1 over
expression plasmids (Foxo1 OE). (B) Real-time RT-qPCR of Fox1 and IFT80 expression levels of MC3T3-E1
cells lines transfected with control (pCMV) or Foxo1 over expression plasmids (Foxo1 OE). (C) IFT80
luciferase reporter assay of Foxo1f/f and Foxo1d/d POBs exposed to 150 µg/ml unmodified BSA or 150 µg/ml
AGEs. Data from three independent experiments. * P < 0.05,  P < 0.01, # P < 0.001.
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Deletion of Foxo1 in osteoblasts lineage could not rescue diabetesimpaired bone formation in IFT80 deficient fracture callus
To investigate if Foxo1 is the major regulator of IFT80 expression in diabetes, we
generated OsxcretTAIFT80f/fFoxo1f/f mice. The mice were then i.p injected with multiple low
dose administration of STZ to indue diabetes. Strikingly, the deletion of Foxo1 in
OsxcretTAIFT80f/f mice could not rescue the diabetes-reduced bone formation. MicroCT
results showed a dramatic reduction in the bone volume of Dia OsxcretTAIFT80f/fFoxo1f/f
calluses compared to normoglycemic control (NG OsxcretTA, P<0.05) and Dia
OsxcretTAFoxo1f/f calluses (P<0.01) (Figure 36. A & B). Double deletion of Foxo1 and IFT80
in osteoblasts of diabetic mice reduced the BV/TV by 41% compared to NG OsxcretTA and
Dia OsxcretTAFoxo1f/f groups. Similar findings were noticed in the Conn-Dense value
(Figure 36. A & B).
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Figure 36. Deletion of Foxo1 in osteoblast lineage cells could not rescue diabetes impaired bone
formation in IFT80 deficient fracture callus. (A) MicroCT scan, 3D reconstruction and of the fracture site
of NG OSXcretTA (control), Dia OSXcretTA, Dia OSXcretTAFoxo1f/f and Dia OSXcretTAIFT80f/fFoxo1f/f mice at D21
post-fracture. (B) Quantitative analysis of the percentage of bone volume to total bone volume (BV/TV)
and connectivity density (Conn-Dens) at fracture site on D21 post-fracture (n=6-8 mice per group).  P <
0.01, # P < 0.001. NG: normoglycemic, Dia: Diabetic. Scale bar: 1mm.

Consistent with microCT, histological analysis showed that deletion of Foxo1 and
IFT80 could not restore BV/TV in Dia OsxcretTA. The BV/TV in Dia OsxcretTAFoxo1f/f was
increased by 1.8-fold compared to that in Dia OsxcretTA. However, Foxo1 deletion in
osteoblasts could not restore the decreased BV/TV in Dia OsxcretTAIFT80f/f mice (Figure
37. A & B). These findings demonstrated that osteoblast-specific Foxo1 deletion rescued
the negative impact of diabetes in fracture healing through regulation of IFT80, and
deletion of IFT80 blocked the rescued effect from Foxo1 deletion.
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Figure 37. Deletion of IFT80 and Foxo1 in osteoblast lineage impaired bone regeneration in fracture callus. (A)
Safranin O staining of longitudinal sections of the fracture site from NG OSX cretTA (control), Dia OSXcretTA, Dia
OSXcretTAFoxo1f/f and Dia OSXcretTAIFT80f/fFoxo1f/f mice at D21 post-fracture. (B) Quantification analysis of bone
area normalized to callus area (BV/TV) at fracture site from D21 post-fracture (n= 5-6 mice per group).  P <
0.01, # P < 0.001. NG: normoglycemic, Dia: Diabetic. Scale bar: 1mm.
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Chapter 5
DISCUSSION
Fracture healing follows a well-organized regeneration model that involves sequential
cellular and molecular events [1–3]. T1DM, which is associated with insulin deficiency,
significantly disrupts the bone healing process, and diabetic patients suffer from delayed
healing and more complications [139–141,165,223]. The negative impact of T1DM on
osteoblasts (essential cells for bone formation) and their progenitor cells has been
extensively studied [224–226]. Various mechanisms, such as increased inflammatory
cytokine expression, enhanced RANKL expression and decreased osteoblast markers,
are associated with diabetes’ negative impact on osteoblast function [212,227–231].
Recently, the critical role of primary cilia in increasing diabetes susceptibility has been
identified. The primary cilia in beta-cells are needed for glucose sensing, activating the
insulin signaling pathway and insulin secretion. Disruption of primary cilia in beta-cells
impairs insulin secretion and glucose homeostasis, leading to the development of diabetes
[160,161,232–234]. Diabetes also negatively impacts the primary cilia in renal tissues.
Increased glomerular filtration rate in the diabetic kidney leads to sustained exposure of
proximal tubular cells to fluid shear stress, which causes cilia disappearance [232].
Diabetes induced by STZ and loss of cilia induced by IFT88 deletion increase inflammation
and accelerate cyst formation in the kidney [233]. Previous studies have shown that
impaired glucose tolerance and diabetes are common in patients with syndromic
ciliopathies such as Bardet-Biedl and Alström Syndromes. However, it has been
completely unknown whether the complications associated with diabetes are linked to
ciliogenesis and how diabetes affects primary cilia formation in bone cells during fracture
healing. In this study, we found for the first time that diabetes disrupts cilia formation in
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osteoblasts and thereby impairs fracture healing, providing new insights into how diabetes
interferes with osteogenesis in fracture repair.
IFT proteins, which serve as a two-way transport system along the ciliary axoneme,
are required in primary cilia assembly and cilia function [53,55,56]. IFT80 is a major
component of IFT complex B. Reduced expression of IFT80 in humans causes Jeune
asphyxiating thoracic dystrophy and short-rib polydactyly type III syndromes, both of which
manifest bone abnormalities [116–118]. Our previous studies revealed that silencing of
IFT80 in murine mesenchymal progenitor cell lines and bone marrow-derived stromal cells
leads to shortening and loss of primary cilia [115]. Our laboratory has also found that IFT80
deletion in OPCs using OSXcretTAIFT80f/f causes significant growth retardation and
osteopenia in the IFT80 mutant mice model. Deletion of IFT80 results in disruption of cilia
formation in OPCs, impairment of osteoblast differentiation and downregulation of
canonical Hh-Gli signaling transduction [120]. These studies indicate that primary cilia and
IFT80 protein play an essential role in osteoblast differentiation and function during bone
development. This study found that IFT80 and primary cilia in osteoblasts are also
required during fracture healing, and diabetes dramatically reduces the cilia formation of
osteoblasts in fractured callus, leading to impaired bone formation. The loss of cilia in
osteoblasts and the reduction in bone formation and mechanical strength were almost
similar in calluses of mice with osteoblast lineage deletion of IFT80 (NG OSXcretTAIFT80f/f)
and diabetic mice (Dia OSXcretTA). Surprisingly, the deletion of IFT80 in diabetic mice (Dia
OSXcretTAIFT80f/f) did not further suppress primary cilia formation, bone formation and
mechanical strength of fractured calluses, reflecting the dramatic effect of diabetes on
ciliogenesis. Although no study has investigated the impact of cilia in diabetic fracture
healing, a recent study has shown the significance of primary cilia in fracture healing [235].
Mice with deletion of IFT88 in mesenchymal stem cells display a significant delay in
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fracture healing with persistent cartilaginous nodules and lack of newly formed bone in
fracture calluses. Disruption of IFT88 leads to loss of cilia, resulting in nonautonomous
regulation of Hh signaling. In addition, deletion of IFT88 downregulates the Wnt signaling,
resulting in increased chondrogenesis and angiogenesis [235]. Noteworthily, Osterix-cre
mediated IFT80 deletion occurs in osteochondroprogenitors [236,237]. Our laboratory has
also revealed the essential role of IFT80 and primary cilia in chondrocytes during fracture
healing. Deletion of IFT80 in chondrocytes dramatically decreased primary cilia formation
in callus chondrocytes, resulting in defective fracture healing with a significant reduction
in the cartilaginous callus formation [126], which is further supported by previous studies
showing that smaller cartilaginous callus is formed in diabetic mice [183,184,238,239].
Mechanistically, diabetes and ablation of IFT80 significantly reduced osteoblast
proliferation and expression of osteoblast markers to a similar extent during fracture
healing. These findings indicate that cilia play an essential role in both proliferation and
differentiation of osteoblasts. Thus, the impaired proliferation and differentiation of
osteoblasts caused by diabetes is likely due to the disruption of ciliogenesis. These
findings are consistent with previous reports that diabetes interferes with osteoblast
proliferation and differentiation in fracture healing [179,180,240]. Consistent with the invivo findings, our in-vitro results demonstrated that AGEs reduced primary cilia formation
in osteoblasts and downregulated IFT80 expression. Both AGEs and IFT80 deletion in
osteoblasts decreased osteoblast differentiation and mineralized matrix formation to a
similar extent. These results also agree with previous studies showing that AGEs impair
osteoblast differentiation [241–243].
Foxo1 transcription factor is the most abundant and studied Foxo member in bone.
Foxo1 regulates gene expression to control many cellular processes, including cell cycle,
survival, differentiation and metabolism [200,202]. Foxo1 positively regulates osteoblast
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differentiation and modulates bone remodeling during bone development [203,244].
During osteoblast differentiation, Foxo1 expression upregulates, which leads to enhanced
expression of osteoblast markers [202,205]. ChIP assays also show Foxo1 interaction
with the promoter of Runx2 and ALP in osteoblasts to regulate osteoblast differentiation,
maturation and mineralization [202,204]. In the current study, we investigated the role of
Foxo1 in osteoblasts during fracture healing. We found that osteoblast lineage deletion of
Foxo1 in normoglycemic mice (NG OSXcretTAFoxo1f/f) significantly decreased bone
formation, resulting in callus with poor mechanical strength. Foxo1 deletion decreased
osteoblast proliferation and downregulated the expression of osteoblast markers in the
callus of NG OSXcretTAFoxo1f/f mice. The in-vitro results further support these in-vivo
findings. Foxo1-deleted POBs (Foxo1d/d POBs) exhibited reduced differentiation as
demonstrated by less alizarin red nodules and diminished osteoblast markers compared
to control cells (Foxo1f/f POBs). Recently, the role of Foxo1 in chondrocytes during fracture
healing has been reported by Ding et al. [206]. In contrast to the fact that Foxo1 positively
regulates osteoblast proliferation and differentiation during fracture healing, they found
that Foxo1 prevents the overproduction of cartilage by limiting chondrocyte proliferation
and matrix marker expression in the early phase of fracture healing. Deletion of Foxo1 in
chondrocytes promotes chondrocyte proliferation by increasing cyclin D1 and reducing
p27 expression levels. Foxo1 ablation also increases the expression of cartilage matrix
genes, such as Col10α1 and aggrecan. The increase in the number of chondrocytes and
matrix production contributes to the increase in cartilage formation in the early phase of
fracture healing (D7 and D10). However, in the later phase of fracture healing (D13 and
D16), Foxo1 deletion enhances osteoclast formation, increases IL-6 and reduces M2
macrophage numbers, leading to a greater loss of cartilage [206]. This regulation results
in a reduced template for bone formation during fracture healing, accompanied by
diminished mechanical strength [187,209]. These results and our findings highlight the
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significance of Foxo1 in regulating chondrocyte and osteoblast function for fracture
healing.
Despite the positive role of Foxo1 in physiologic fracture healing [203], Foxo1 plays a
negative role in pathologic conditions. In diabetes, characterized by high glucose and
AGEs, inflammation is elevated and Foxo1 activation upregulates [183,208,217]. For
example, diabetes increases chondrocyte and MSCs apoptosis through enhanced
production of TNF-α, which has been shown to result from diabetes-induced Foxo1
overactivation

[182,184].

Diabetes-enhanced

Foxo1

expression

also

increases

chondrocyte-expressing RANKL in the fracture callus, leading to enhanced osteoclast
numbers [209]. In this study, we found that Foxo1 expression significantly upregulated in
diabetic callus (Dia OSXcretTA) compared to the control mice (NG OSXcretTA), leading to a
dramatic reduction in the callus bone volume and mechanical strength as measured by
the torsion analysis. Interestingly, osteoblast lineage deletion of Foxo1 completely
reversed the negative impact of diabetes on the bone volume and mechanical strength to
levels similar to those in the control mice (NG OSXcretTA). Consistent with our findings,
previous studies have found that chondrocyte lineage deletion of Foxo1 rescues the
premature resorption of cartilage and subsequent impaired bone formation and
mechanical strength in diabetic fracture healing [209,245]. Foxo1/3/4 also exacerbates
diabetic bone loss, and deletion of Foxo1/3/4 in the osteoblast lineage abrogates the
diabetes-induced bone loss by preventing the reduction in OPG and the increase in
osteoclasts [83].
Mechanistically, our data show that diabetes-induced Foxo1 overexpression inhibits
IFT80 expression and subsequent cilia formation. Strikingly, osteoblast lineage deletion
of Foxo1 reversed the diabetes-reduced IFT80 expression and cilia formation, which
restored the proliferation and differentiation of osteoblasts in Dia OSXcretTAFoxo1f/f mice.
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To our knowledge, this is the first study to show that the Foxo1 transcription factor
regulates IFT80 gene expression under diabetic conditions. Some studies have reported
the transcriptional control of Foxj1 and several members of the regulatory factor X (RFX)
in ciliogenesis [246,247]. Foxj1 plays a critical role in motile cilia formation by controlling
the expression of the axonemal dynein (Dnahc11) gene, which is essential for cilia motility,
and loss of Foxoj1 compromises the motile cilia formation [248,249]. Several members of
RFX are also crucial for either primary or motile cilia formation by regulating the expression
of dynein motor proteins and components of IFT-B and BBS complexes [250–252].
Although these transcriptional factors are positive regulators of ciliogenesis, our results
show that Foxo1 is a negative regulator of ciliogenesis by suppressing the expression of
the IFT80 gene in diabetic conditions. Some studies have shown that Foxo1 binds to the
promoters of different genes to increase their expression [253–255]. Foxo1 binds to the
apolipoprotein apoC-III promoter in hepatocytes and enhances its transcription to mediate
triglyceride metabolism [255]. Foxo1 directly upregulates Bim gene expression and
promotes apoptosis in human lung cancer cells [254]. In diabetes, Foxo1 interaction
increases with the promoters of pro-inflammatory genes such as MMP9 and CCL20 and
substantially enhances their expression, which interferes with the wound healing process
[256,257]. Diabetes also enhances Foxo1 DNA binding to TNF-α and RANKL promoters
to increase the expression of those genes in diabetic fracture calluses [183,209]. Based
on our knowledge, this study is the first to demonstrate that Foxo1 acts as a suppressor
to transcriptionally regulate gene expression.
Previous studies have shown that diabetes reduces the interaction of Foxo1 with the
TGF-β1 promoter in keratinocytes, and TGF-β1 expression is required for keratinocyte
migration and reepithelization during wound healing [258,259]. Interestingly, TGFβ
signaling is critical in skeletal integrity and hemostasis, and TGFβ receptors have been
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demonstrated to localize into the cilia in response to TGFβ stimulation to initiate a cascade
of signaling events in the cytoplasm [51,260]. Our laboratory has shown that IFT80 protein
plays a critical role in the regulation of TGFβ receptor localization in primary cilia and the
downstream activation of TGFβ-Smad signaling in chondrocytes [126]. Strikingly, Foxo1
has been shown as a key downstream target of TGFβ signaling in regulating the cartilage
hemostasis by transcriptional control of autophagy-related genes (Maplc3b and Becn1) in
chondrocytes [261]. These studies provide a new understanding of the possible link
between primary cilia, TGFβ signaling and Foxo1 in chondrocytes.
In this study, our focus was on better understanding the underlying mechanism of
T1DM impact on fracture healing. Thus, we used the STZ-induced T1DM model, a wellestablished diabetic model with many similarities to T1DM complications in humans, such
as chronic hyperglycemia, impaired bone quality and reduced bone strength
[166,168,169]. However, STZ at high doses adversely affects other organs, including
kidneys, liver and heart. To reduce the nonspecific toxicity, STZ was administered in
multiple injections of low doses to cause repeated low-grade beta-cell damage [262–264].
Destruction of beta-cells in T1DM causes insulinopenia in combination with a low level of
IGF1, which leads to decreased bone formation in the early stages of the disease [265–
268]. Therefore, subjects with T1DM are usually associated with a reduction in BMD and
a significant increase in fracture risk. In contrast, individuals with T2DM have higher BMD
than non-diabetic individuals and increased fracture risk [164,269–272]. The higher BMD
in individuals with T2DM is probably due to the mechanical adaptation to higher body
weight and hyperinsulinemia that may promote bone formation [272–276]. The
mechanism underlying the association between higher BMD and increased fracture risk
in patients with T2DM is still elusive. Many factors associated with diabetes, such as
hyperglycemia, development of AGEs, chronic inflammation and microvascular diseases,
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may negatively affect bone architecture in T2DM patients and predispose the patients to
higher risk of fracture [277–280]. The current study delineated a novel underlying
mechanism of T1DM-induced impaired bone healing. This study provides the first
evidence to propose diabetic-enhanced Foxo1 activity mediated inhibition of IFT80
expression and subsequent disruption in primary cilia in osteoblasts, resulting in diabetic
defective fracture healing. It would also be interesting to study the impact of T2DM on
primary cilia and whether this impact is mediated through Foxo1. Only one study has
shown that the clinical application of a Foxo1 inhibitor (AS1842856) improves early wound
healing in a T2DM minipig model by reducing inflammation, improving angiogenesis and
increasing collagen matrix formation and myofibroblast numbers [281].
Besides the negative impact of diabetes on fracture healing, diabetes is one of the
major risk factors for periodontitis [282]. According to a report from the American Academy
of Periodontology, periodontitis is a microbially-associated, host-mediated inflammation
that results in loss of periodontal attachment [283]. Diabetes alters the host response to
bacterial challenge, and thereby makes diabetic patients more prone to periodontitis
development. Studies have shown that diabetes affects the innate and adaptive immune
cells, both of which are required to respond to oral bacterial challenges in mucosal tissues
and maintain mucosal homeostasis [282,284]. In addition, altered bone metabolism
associated with diabetes adversely affects alveolar bone remodeling via accelerating bone
resorption [282,284]. It is worth mentioning that the risk of periodontitis is about three to
four times higher in individuals with diabetes compared to non-diabetic subjects [285–
287]. Interestingly, Foxo1 has been shown to play a critical role in the host defense
response in periodontal tissue. Foxo1 affects macrophage and neutrophil recruitment and
activation, and dendritic cell function as well as differentiation of adaptive immune cells
[282,284,288,289]. In addition, Foxo1 is one of the key regulators in osteoblast function.
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Osteoblasts have been demonstrated to contribute to periodontal bone loss [290].
Periodontal infection increases RANKL expression and NF-κB nuclear localization in
osteoblasts, leading to enhanced osteoclast formation, increased bone resorption and
decreased reparative new bone formation [290]. Therefore, an alternation in Foxo1 activity
may significantly affect periodontal disease susceptibility and development, given
numerous studies have shown that diabetes induces Foxo1 overactivation, and the latter
is highly associated with diabetic complications [188–190]. Interestingly, in the present
study we found the novel association between diabetes-induced Foxo1 overactivation and
primary cilia in osteoblasts. Foxo1 and primary cilia in periodontal mucosal tissue and oral
osteoblast of diabetic mice might also be related to increasing periodontitis susceptibility,
which would be interesting to investigate in the future.
Unexpectedly, we found that Foxo1 significantly inhibits expression of the IFT80 gene
and cilia formation in diabetic conditions but not in normoglycemic conditions. Moreover,
Foxo1 is essential for normal osteoblast differentiation and bone formation. One possibility
is that a physiological level of Foxo1 expression is required for osteoblast activity, but it
does not impact IFT80 expression and cilia formation. However, in diabetic conditions
where the level of Foxo1 expression is dramatically elevated, Foxo1, as a transcription
factor, suppresses the IFT80 gene expression, and thereby reduces cilia formation and
inhibits osteoblast function. Further studies could explore whether Foxo1 can undergo
post-translational modification such as acetylation or phosphorylation in the promoter
region of IFT genes to turn down these genes’ expression. Additionally, it would be
interesting to investigate whether other proteins can bind to Foxo1 and function as
coactivators or corepressors to regulate the expression of ciliary genes such as IFT80
[208,291].
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Young adults (18-30 years old) with T1DM suffer from a significantly higher fracture
risk than non-diabetic counterparts. The impact of fracture in a young adult is devastating,
with consequences of physical and psychological morbidity and increased mortality
[268,292,293]. In this study, we used the time point of three months old for performing the
murine fracture model, and harvesting the fracture femur calluses ranged between three
to six months old. This is the most widely used age for performing the murine closed
femoral fracture model in diabetic models [182,187,209]. In addition, three to six months
old mice are considered mature adults with mature bone, equivalent to young adult
humans aged 20-30 years old [294]. Thus, the results from this study demonstrate more
clinical relevance to human diabetic fracture healing.
AGEs are complex and heterogenous compounds formed via nonenzymatic reactions
between reducing sugars and amine residues on proteins, lipids or nucleic acids. AGEs
formation is strongly accelerated in diabetes due to long-term hyperglycemia [295].
Studies have also shown a significant increase of AGEs formation in STZ-induced diabetic
mice [296,297]. In order to analyze the effects of AGEs on ciliogenesis, we performed
dose optimization experiments and found that 150 ug/ml concentration of AGEs or below
did not affect osteoblast survival. Therefore, we chose this dose to analyze the cilia
formation. However, one of the negative impacts of AGEs on bone formation is that high
concentrations of AGEs (above 200 ug/ml) can induce apoptosis in osteoblasts [241,243].
Therefore, further studies could investigate whether osteoblast apoptosis results from cilia
loss induced by high doses of AGEs. Additionally, we used an anti-acetylated α-tubulin
antibody to detect the ciliary axoneme. This antibody is one of the most widely used
markers for detecting cilia [298,299]. Acetylated microtubules are also present in the
cytoskeleton of cells apart from the cilia [300]. However, we captured Z-stacked images
to confirm the signal in the ciliary structure. Better validation could be obtained using
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double markers such as an acetylated α-tubulin marker with a centrosome marker, γtubulin, that stains the basal bodies at the base of the cilium to identify the α-tubulin signal
that corresponds to the cilium. The Osx-cre mice model carries reverse tetracycline–
dependent transactivator (rtTA), in which administration of tetracycline (or its more stable
derivative, doxycycline) inactivates the Cre expression. When tetracycline administration
is withdrawn, the Cre expression initiates [216]. To prevent IFT80 and Foxo1 deletion
during the embryonic and developmental stages, we administered water containing 2
mg/ml of doxycycline to single and double knockout mice to inhibit Cre expression. Our
results have shown no IFT80 leakiness before performing the fracture model. Thus, the
findings from these experiments exclude the possible effects of IFT80 and Foxo1
deficiency at developmental stages on diabetic fracture healing.
In summary, we found the significant role of IFT80/primary cilia in modulating normal
fracture healing and delineated one new mechanism by which diabetes impairs fracture
healing. Our results for the first time identified that diabetes-enhanced Foxo1 expression
inhibits IFT80 gene expression, which subsequently disrupts ciliogenesis and
osteogenesis, leading to defective fracture healing. Future studies could investigate
whether overexpressing IFT80 in STZ-induced diabetic mice using a gene therapy
approach can restore the diabetic inhibitory effect on cilia loss and defective fracture
healing [301]. Additionally, inhibition of Foxo1 by local application of a Foxo1 inhibitor
(AS1842856) or siFoxo1 in diabetic fracture calluses would expand the validity and
translational application of the current study. Moreover, the present study focuses on the
Foxo1 regulatory effect on IFT80 promoter and gene expression. Although our ChIP assay
and luciferase results demonstrated that Foxo1 transcriptionally inhibits IFT80 expression,
a more comprehensive study would be valuable in order to identify other ciliary gene
expressions under the control of Foxo1 using a ChIP-sequencing assay to reveal the
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Foxo1 regulation in ciliogenesis. Lastly, our laboratory has found that local delivery of IGF1 and IGF-1 peptides promotes diabetic fracture healing and ciliogenesis. Further studies
are required to determine whether the insulin/IGF-1 signaling pathway regulates
ciliogenesis at upstream of the Foxo1 signaling in diabetic fracture healing. This finding
will reveal a new molecular mechanism in diabetic fracture healing and lead to the
development of new therapeutic strategies to enhance diabetic bone repair by modulating
ciliogenesis.
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Chapter 6
CONCLUSIONS
➢ Primary cilia play an indispensable role in fracture healing and restoration of
bone mechanical strength.
➢ IFT80 deletion in osteoblasts causes cilia loss and impairs fracture healing.
➢ Diabetes negatively affects IFT80 expression and ciliogenesis in fracture callus,
which compromises fracture healing.
➢ Deletion of IFT80 and diabetes both impair cilia formation to a similar extent,
which suggests that diabetes-reduced ciliogenesis in osteoblasts is one of the
key events in diabetes-impaired fracture healing.
➢ Diabetes upregulates Foxo1 activity, which decreases IFT80 expression level.
➢ Diabetes-induced Foxo1 overactivation reduces IFT80 expression, which
subsequently disrupts cilia formation in diabetic fracture healing, resulting in
impaired diabetic fracture healing.
➢ Ablation of Foxo1 in osteoblasts restores diabetes-reduced IFT80 expression,
cilia loss, bone formation and mechanical strength during fracture healing.
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